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ABSTRACT OF THE DISSERTATION 
The Role of Novel Gene UL79 Encoded by Human Cytomegalovirus in Viral Replication 
by 
Yi-Chieh Perng 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Microbiology and Microbial Pathogenesis 
Washington University in St. Louis, 2014 
Professor Deborah J Lenschow, Chairperson 
 
        Human cytomegalovirus (HCMV) is a ubiquitous pathogen that infects the majority of the 
world’s population.  Even though HCMV infection is usually asymptomatic, it acts as an 
opportunistic pathogen and is the major cause of morbidity and mortality in 
immunocompromised individuals, including transplant recipients and AIDS/HIV patients.  
Understanding HCMV biology is critical to the development of HCMV therapeutics.  However, 
our current knowledge of HCMV biology is limited by the fact that only less than half of the 
HCMV genes have been characterized, especially viral essential and augmenting genes which 
play critical roles in viral replication.   
        To study the function of HCMV essential and augmenting genes, we devised a conditional 
approach to facilitate the analysis.  In this approach, we constructed recombinant virus where the 
viral open reading frame (ORF) of interest is tagged with the destabilization domain FKBP 
(ddFKBP) which targets the fusion protein for rapid degradation.  However, the fusion protein 
can be stabilized by the synthetic ligand Shield-1 (Shld-1).  This system allows us to monitor the 
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effects of the viral protein on the HCMV life cycle simply by infecting human fibroblasts in the 
presence or absence of Shld-1. 
        We adopted this conditional protein genetic approach to characterize the role of the human 
cytomegalovirus (HCMV) gene UL79 during virus infection.  We constructed ADddUL79, a 
recombinant HCMV in which the annotated UL79 open reading frame (ORF) was tagged with 
ddFKBP.  ADddUL79 failed to replicate without Shield-1, but it grew at wild-type levels with 
Shield-1 or in human foreskin fibroblasts overexpressing hemagglutinin (HA)-tagged UL79 (HF-
UL79HA cells), indicating an essential role of UL79 and the effectiveness of this approach.  
Without Shield-1, representative immediate-early and early viral proteins as well as viral DNA 
accumulated normally, but late transcripts and proteins were markedly reduced.  UL79 was 
transcribed with early-late kinetics, and was also regulated via a positive-feedback loop.  We also 
found that the UL79 protein localized to viral replication compartments during HCMV infection.  
Moreover, we created a second UL79 mutant virus (ADinUL79stop) in which the UL79 ORF was 
disrupted by a stop codon mutation and found that ADinUL79stop phenocopied ADddUL79 under 
the destabilizing condition.  Taking together, we showed that UL79 acts after viral DNA 
replication to promote the accumulation of late viral transcripts.   
         To test how pUL79 regulates viral late gene transcription, we analyzed the proteome 
associated with pUL79 during virus infection by mass spectrometry.  We identified both cellular 
transcriptional factors, including multiple RNA polymerase II (RNAP II) subunits, and novel 
viral transactivators, including pUL87, pUL92, and pUL95, as protein binding partners of 
pUL79.  Co-immunoprecipitation (co-IP) followed by immunoblot analysis confirmed the 
pUL79-RNAP II interaction, and this interaction was independent of any other viral proteins.  
We showed that this interaction did not alter the total levels of RNAP II or its recruitment to viral 
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late promoters.  Furthermore, pUL79 did not alter the phosphorylation profiles of the RNAP II 
C-terminal domain, which is critical for transcriptional regulation.  Rather, nuclear run-on assay 
indicated that, in the absence of pUL79, RNAP II failed to elongate and stalled on viral DNA.  
Surprisingly, pUL79-dependent RNAP II elongation was required for transcription from all three 
kinetic classes of viral genes (i.e. immediate-early, early, and late) at late times during virus 
infection.  In contrast, host gene transcription during HCMV infection was independent of 
pUL79.  In summary, we have identified a novel viral mechanism by which pUL79 regulates the 
rate of RNAP II transcription machinery on viral transcription during late stages of HCMV 
infection. 
        Together these data provide important insight into how HCMV uses pUL79 to promote 
viral transcription specifically during late stages of viral infection.  Understanding the 
mechanisms by which pUL79 regulates RNAP II elongation as well as its association with other 
viral factors will aid in the development of future therapeutics against HCMV infection. 
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Chapter 1: 
 
 
Introduction 
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INTRODUCTION 
HCMV as human pathogen.  Human cytomegalovirus (HCMV), the prototypic β-
herpesvirus, is a ubiquitous pathogen that infects the majority of the world’s population.  
Upon primary infection, HCMV establishes a lifelong persistent and latent/recurrent infection 
in a host(12).  Even though HCMV infection is usually asymptomatic, it acts as an 
opportunistic pathogen and is the major cause of morbidity and mortality in 
immunocompromised individuals, including transplant recipients and AIDS/HIV 
patients(13).  In addition, HCMV is the leading viral cause of birth defects leading to mental 
retardation and blindness.  Each year, HCMV infects approximately 30,000 newborns, 
causing an estimated 400 deaths and 5,000 disabilities in the United States alone(1).  The 
health and economic impact of HCMV infection is tremendous.  The healthcare cost 
associated with HCMV-related disease in the United States is estimated at 4 billion dollars 
per year(22).  Moreover, there is evidence for HCMV to act as a risk factor in the 
development of vascular diseases, such as atherosclerosis, transplant vascular sclerosis, and 
coronary restenosis after angioplasty surgery(19, 26, 32, 36, 48, 52, 59).  Recently, a role for 
HCMV has also been implicated in multiple forms of human cancers, where it may contribute 
to oncogenic transformation, onco-modulation, and tumor cell immune evasion(6, 16, 23, 
42). 
 
HCMV therapeutics.  To date, a limited number of drugs are licensed for the treatment of 
HCMV infection and no vaccine is available(1).  Current standard therapy for HCMV relies 
on oral/intravenous ganciclovir (GCV) or its oral prodrug, valganciclovir (VGCV).  Although 
efficacious, GCV treatment suffers from dose-related toxicities.  Forscarnet (FOS) and 
cidofovir (CDV), the two commonly used second-line treatments for HCMV, are also 
associated with significant toxicities, including renal toxicity.  In addition, during 
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prolonged/repeated application, HCMV can become resistant to GCV and lead to treatment 
failure in immunocompromised patients.  Of concern, GCV resistance in HCMV infections 
has increased during recent years, and the emergence of cross-resistance to either or both 
second-line agents (FOS & CDV) is frequently encountered because all licensed drugs share 
a common target molecule, the viral DNA polymerase, pUL54(28).  Moreover, all current 
HCMV antivirals are teratogenic, mutagenic, and potential carcinogens(4, 24, 27, 29).  The 
dosing limitations due to toxicities further facilitate the emergence of drug-resistance.  
Currently no HCMV vaccine is available(1).  Therefore, there is an urgent need to develop 
new, safe, and efficacious antiviral drugs.  A better understanding of HCMV biology, its 
interactions with the host, and pathogenesis is critical for us to develop novel and more 
effective antiviral therapeutics to control this globally important pathogen. 
 
HCMV biology and reverse genetics.  HCMV is the largest known human virus with a 
genome of ~240 kb encoding at least 166 annotated viral open reading frames (ORFs)(37, 38) 
and several miRNAs(15, 21).  The viral genome is composed of a unique long (UL) and a 
unique short (US) region with repeated segments at the end of each region, namely TRL/IRL 
and TRS/IRS, respectively.  ORFs are numbered sequentially in each region. HCMV displays 
a lifecycle very similar to other herpesviruses but with a slow replication kinetics, as the virus 
does not produce progeny virions until 48-72 hours after infection in primary human 
fibroblast cultures in vitro.  After binding and internalization, the viral DNA is transported to 
the nucleus after which the immediate-early transcripts are expressed.  Viral DNA replication 
occurs between 24 and 48 hours after infection followed by late gene expression and capsid 
assembly.  Capsids are then translocated out of the nucleus and acquire their envelope in the 
cytoplasm.  Once virions are formed they exit the cell beginning around 48 hours post 
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infection and continuing for several days until the cell dies(17).  The lytic infection cycle of 
HCMV is also diagramed in Figure 1.1. 
     HCMV exhibits strict host specificity as it can only infect human cells.  On the other hand, 
HCMV can infect a wide range of cell types in its natural host, including epithelial cells, 
endothelial cells, smooth muscle cells, fibroblasts, neurons, and macrophages.  The virus 
spreads systemically via a leukocyte-associated viremia, and the primary infection can 
continue for months in adults and years in children.  Following the prolonged acute infection 
the virus enters a lifelong latent state in lineage- committed myeloid cells and possibly 
endothelial cells.  The latent virus can then reactivate following differentiation of latently 
infected cells into cells permissive for HCMV lytic infection, the reduction in immune 
pressure, or due to other unknown determinants(17).  
     Laboratory-adapted strains of HCMV, such as AD169 and Towne, have been widely used 
to study HCMV biology.  The laboratory-adapted strains were created by passaging the virus 
in fibroblasts for > 100 times in an effort to create a live attenuated vaccine. These strains 
replicate efficiently in fibroblasts but inefficiently in other cell types, such as endothelial 
cells, epithelial cells, and macrophages(17), which are readily infected by clinical strains of 
HCMV.  In AD169, this loss in cell tropism can be partially attributed to mutation in the 
UL131 genes, as an AD169 variant which has the UL131 gene repaired can efficiently infect 
both epithelial and endothelial cells(55, 56).  We and others have cloned laboratory strains 
(AD169 and Towne)(58), low-passage strain (Toledo), as well as several clinical isolates (TR 
and Fix) as infectious bacterial artificial chromosomes (BAC) and developed BAC-based 
reverse genetic system for HCMV.  The advent of the HCMV reverse genetics greatly 
enhances our ability to dissect the molecular mechanisms underlining its biology and 
pathogenesis(39). 
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Expression kinetics of HCMV genes.  During lytic infection, HCMV genes are expressed in 
a highly ordered temporal cascade(3, 34, 50, 57).  Viral transcripts accumulate with three 
kinetic classes, namely immediate-early, early, and late.  The HCMV major IE (MIE) genes 
UL123 (IE1) and UL122 (IE2) play critical roles in predisposing the cellular environment to 
infection and also act as transactivators to induce early gene transcription.  Many early genes 
encode proteins required for viral DNA synthesis(18, 20, 51).  The transcript accumulation of 
early genes is independent of viral DNA synthesis; however, the continued accumulation of a 
subset of these genes at late times is enhanced by the onset of viral DNA synthesis(49).  
Following viral DNA synthesis, late viral genes start to transcribe, which mostly encode 
structural proteins required for virus assembly and egress, ultimately leading to the release of 
infectious particles.  Previous studies have shown that the activation of both beta- and 
gamma-herpesvirus late gene promoters is dependent on the origin of viral DNA synthesis 
(OriLyt) in cis(2, 14, 35).  This further supports the notion that late gene transcription is 
tightly coupled to viral DNA synthesis.  However, whether viral late gene expression is 
subjected to additional viral regulation remains poorly defined.  
 
RNA polymerase II (RNAP II) transcribe HCMV genes.  During cytomegalovirus 
infection, viral genes are transcribed by cellular RNA polymerase II (RNAP II), a large 
multi-subunit enzyme.  Rpb1, the largest subunit of RNAP II, has a carboxy terminal domain 
(CTD) that contains repeats of the heptapeptide sequence of Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-
Ser7(11).  The mammalian CTD is compromised of 52 copies of heptapepetides(8).  This 
unstructured domain is strategically located adjacent to the mRNA exit channel of the 
enzyme.  This helps the CTD act as a scaffold to coordinate interactions with proteins 
involved in different phases of transcription and allow for the coupling of transcription with 
other nuclear processes, such as mRNA maturation and chromatin modification(40, 46).  The 
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amino acids within the CTD repeats are targets for post-translational modifications, including 
phosphorylation, glycosylation, ubiquitination, and cis-trans isomerization(10).  Different 
combinations of CTD modifications, known as the CTD codes, orchestrate the sequential 
recruitment of numerous factors during the transcription cycle(7). 
          RNAP II activity is tightly regulated by phosphorylation of its CTD.  RNAP II is 
recruited to preinitiation complexes (PIC) in an unphosphorylated state(30).  Following the 
binding of RNAP II to a promoter, serine 5 residue of the CTD (Ser5) is rapidly 
phosphorylated by cdk7, the kinase subunit of the transcription factor TFII-H.  This facilitates 
the dissociation of RNAP II from the PIC(47), and also promotes the recruitment of capping 
and splicing factors as well as other histone modification complexes(40).  After dissociating 
from PIC, RNAP II proceeds to intrinsic pausing sites where it is halted by negative 
elongation factors (NELFs).  The onset of productive elongation requires the positive 
transcription elongation factor P-TEFb composed of cdk9 and cyclin T, which 
phosphorylates serine 2 residue (Ser2) of the CTD to produce stable elongation 
complexes(31).  Ser2 phosphorylation also couples RNA synthesis with RNA processing by 
promoting the recruitment of splicing and polyadenylation factors(41).  At the 3’ end of the 
coding region, RNAP II dissociates from the DNA template and RNA transcript prior to 
transcript polyadenylation.  Specific phosphatases, Ssu72 and Fcp1, also dephosphorylate the 
CTD.  Thus, RNAP II is recycled as an unphosphorylated, initiation-competent form for 
another round of transcription(9, 25). 
            HCMV utilizes RNAP II and the accompanying host machinery for transcription of 
viral genes.  During early times of viral infection, RNAP II and other transcription machinery 
are recruited to early replication sites to drive viral IE and early gene expression(53).  The 
protein levels of RNAP II, including hyper-phosphorylated forms, increase as infection 
progresses(53, 54).  Treatment of infected cells with cdk inhibitors inhibits viral gene 
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expression as well as viral replication(43).  During late stages of viral infection, cdk kinase 
and RNAP II-associated transcriptional machinery proteins continue to accumulate and 
relocate into the peri-replication center(54).  However, how RNAP II transcription machinery 
remains active on viral loci during late infection requires further investigation. 
 
Functional profile of HCMV genes.  Our current knowledge of HCMV biology is limited 
by the fact that only less than half of the HCMV genes have been characterized. With the 
development of the BAC-based genetic system for HCMV, our group and others have used 
global mutagenesis approaches to delineate the functions of the genes encoded by 
HCMV(58).  These studies led to the creation of a functional genomic map for HCMV strains 
AD169 and Towne.  In AD169, we identified 3 different classes of genes based on how they 
are required for virus growth properties in human foreskin fibroblasts (HFFs) (Figure 1.2).  
There were 39 essential gene (mutants that produce no infectious particles), 100 nonessential 
genes (mutants that had no growth defect in human fibroblasts), and 27 augmenting genes 
(mutants that produced small plaques or had a >10 fold in replication on HFFs(58).  Among 
66 essential and augmenting viral genes, 25 of them remain uncharacterized and their roles in 
HCMV infection are completely unknown.  This is because complementing cells that support 
growth of null mutants are difficult to obtain for β- and γ- herpesviruses, such as HCMV, and 
therefore it is often difficult, if not impossible, to generate recombinant HCMV viruses, 
especially the ones defective in essential genes.  Currently, only a very few complementing 
cell lines have been documented for HCMV mutant viruses(33, 44, 45).  As essential and 
augmenting genes are critical for efficient virus growth, insight into functions of these genes 
is a prerequisite for the rational development of antiviral compounds and vaccine vectors. 
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ddFKBP complement system.  To study the function of HCMV essential and augmenting 
genes, an efficient genetic system is the prerequisite tool.  Null mutants of essential genes 
produce no progeny and the ones of augmenting genes may have severe growth defects and 
produce low viral titers, thus impeding the functional characterization of these genes.  The 
conventional complementing approach, namely the use of cells expressing mutated gene 
products to support growth of null mutants, have been reported for only a very few HCMV 
genes because it is difficult to obtain such complementing cells for slowing replicating β-
herpesviruses(33, 44, 45).  Therefore, development of an alternative and efficient 
complementation system is necessary for functional studies of HCMV essential and 
augmenting genes.   
     To overcome this hurdle, we devised a conditional approach to facilitate the analysis of 
viral proteins critical to viral growth and pathogenesis.  A new approach to conditionally 
regulate proteins has been established by tagging a protein with a 102-aa unstable variant of 
the FKBP12 protein (ddFKBP)(5).  In this approach, we construct recombinant virus where 
the viral open reading frame (ORF) of interest is tagged with the destabilization domain 
FKBP (ddFKBP) which targets the fusion protein for rapid degradation(5).  However, the 
fusion protein can be stabilized by the synthetic ligand Shield-1 (Shld-1).  This system allows 
us to monitor the effects of the viral protein on the HCMV life cycle simply by infecting 
human fibroblasts in the presence or absence of Shld-1 (Figure 1.3). 
 
Create a library of recombinant HCMV viruses where accumulation of novel essential 
and augmenting viral proteins can be regulated by ddFKBP-based protein genetic 
approach.   Twelve essential genes and 13 augmenting genes for which null mutants have 
severe growth defects have not been characterized because of the lack of efficient 
complementing system (Table 1.1).  We created recombinant HCMVs in which these 25 viral 
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genes were tagged with ddFKBP.  The 25 genes that were chosen for this study fit two 
criteria: 1) these genes are either essential or augmenting for HCMV replication in 
fibroblasts; 2) these genes and their homologous in other herpesviruses have not previously 
been characterized.  Using linear recombination, we constructed 24/25 ddFKBP fusions to 
create conditional recombinant viruses for further analysis. (Table 1.1) Recombinant BAC 
clones for 10 essential genes and 9 augmenting genes had been electroporated into HFFs to 
reconstitute recombinant viruses in the presence of Shld-1.  Among these 19 recombinant 
viruses, the ones for UL71(ADddUL71), UL77(ADddUL77), UL79(ADddUL79), 
UL91(ADddUL91), and UL103(ADddUL103), were efficiently regulated by Shld-1 
(Table.1.1).  In the presence of Shld-1, these recombinant viruses replicated at wild-type 
levels while in the absence of Shld-1 recombinant viruses reconstituted from BAC 
transfection were not detected (Growth curves of representative genes shown in Figure 1.4). 
 
Goal of the dissertation.  The ddFKBP-based viral genetic system allow us to propagate 
recombinant viruses for multiple candidate viral genes, and a prioritization is necessary for us 
to select one viral gene for further analysis.  Among the five genes that can be regulated by 
ddFKBP, UL79 was shown to be required for late stages of viral infection in our preliminary 
analysis (Data not shown).  HCMV late gene expression is critical to viral replication, 
however, how and what viral factors regulate it was completely unknown.  Therefore, we 
chose UL79 for further analysis.  In this dissertation, we characterized the function of UL79 
during viral infection and elucidated the mechanism of how it facilitates HCMV gene 
expression and viral growth. 
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FIGURES 
 
Figure 1.1.  Lytic infection cycle of HCMV.   
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Figure 1.2.  Functional Map of the HCMV Genome.  ORFs are color coded according to 
whether they are essential (blue) or nonessential (red), or augment (green) replication in 
human fibroblasts (HFFs).  For essential genes, the electroporated BACs of recombinant 
HCMV generated GFP-positive cells 2-3 days after electroporation but failed to produce 
virus. For augmenting genes, the BACs produced small plaques and/or generated ≥10-fold 
Fig. 2. Functional map of the HCMV genome. The genome of HCMV strain AD169 is presented as a series of lines with approximate nucleotide sequence
positions indicated to the right of each line. Above the viral genome, solid arrows represent putative ORFs predicted by Davison et al. (3), and open arrows
repres nt additional ORFs predicted by the original annotation of Chee et al. (2) a d the r cent reannotation of Murphy et al. (4). The subset f mutants fr m
the BAC library whose growthwas analyzed in fibroblasts are positioned on themap below the viral genome, and the nature of eachmutation is indicated: Tn5
insertions (TN), Tn1721 insertions (TS), and mutations made by linear recombination (DH). ORFs are color coded according to whether they are essential (blue)
or nonessential (red), or augment (green) replication in fibroblasts. ORFs without an insertion or substitution notation were classified on the basis of earlier
published reports. The terminal repeat long (TRL) sequence and the internal repeat long (IRL) sequence that is identical to the TRL sequence but in the inverted
orientation are indicated as orange arrows on the viral genome. Only the set of ORFs in the TRL region is displayed because the set of ORFs in IRL are identical,
and we did not distinguish which repeat contained the mutations.
12398 ! www.pnas.org"cgi"doi"10.1073"pnas.1635160100 Yu et al.
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reduced yields of cell-free virus. For nonessential genes, the electroporated BACs produced 
normal-sized plaques and virus stocks with wild-type yields(58) 
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Figure 1.3.  Using ddFKBP-Shield-1 System to Conditionally Control Protein Stability. 
Fusion of a destabilizing domain ddFKBP (DD) to a protein of interest (POI) results in 
degradation of the entire fusion. Addition of a Shield-1, a ligand for the destabilizing domain, 
protects the fusion from degradation(5). 
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fusion.  Addition of a Shield-1, a ligand for the destabilizing domain, protects the fusion from 
degradation (2). 
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Figure 1.4.  Growth kinetics of the recombinant HCMV in the presence or absence of 
Shield-1.  Fibroblasts infected with the ADddUL71, ADddUL77, and ADddUL79 
recombinant viruses were cultivated with or without 1 µM Shield-1.  At the time points 
indicated, supernatants were collected and analyzed for the presence of virus by TCID50 
assays on fibroblasts maintained in 1 µM Shield-1 (Shld1/Shld1).  To test for leakiness of the 
system, supernatant of infected cells grown in the absence of Shield-1 was assayed by 
TCID50 on cells receiving the Shield-1 ligand (nonShld-1/Shld1).  To test the occurrence of 
0 5 10 15 20
100
101
102
103
104
105
106
107
108
Days post infection
vi
ra
l t
ite
r (
TC
ID
50
/m
l)
ADddUL71 MOI 0.1
ADwt
ADddUL71 (Shld1/Shld1)
ADddUL71 (nonShld1/Shld1)
ADddUL71 (nonShld1/nonShld1)
0 5 10 15 20
101
102
103
104
105
106
107
108
Days post infection
vi
ra
l t
ite
r (
TC
ID
50
/m
l)
ADddUL77 MOI 0.1
ADwt
ADddUL77 (Shld1/Shld1)
ADddUL77 (nonShld1/Shld1)
ADddUL77 (nonShld1/nonShld1)
0 5 10 15 20
101
102
103
104
105
106
107
108
Days post infection
vi
ra
l t
ite
r (
TC
ID
50
/m
l)
ADddUL79 MOI 0.1
ADwt
ADddUL79 (Shld1/Shld1)
ADddUL79 (nonShld1/Shld1)
ADddUL79 (nonShld1/nonShld1)
!! 15!
revertant viruses, both the growth curve and the TCID50 assays were performed in the 
absence of Shield-1 (nonShld1/nonShld1). 
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TABLES 
gene type size 
ddFKBP-
tagged 
BAC 
BAC DNA 
transfected 
Regulated 
by Shld-1 
Grow like 
wt without 
Shld-1 
Virus do not 
grow with 
Shld-1 
UL103 augmenting 28 kDa √ √ √     
UL71 augmenting 40 kDa √ √ √     
UL91 essential 12 kDa √ √ √     
UL77 essential 71 kDa √ √ √     
UL79 essential 34 kDa √ √ √     
US26 augmenting 66 kDa √ √     √ 
UL27 augmenting 70 kDa √ √   √   
UL72 augmenting 40 kDa √ √     √ 
UL76 augmenting 36 kDa √ √   √   
UL124 augmenting 17 kDa √ √   √   
UL35 augmenting 71 kDa √ √   √   
UL32 essential 115 kDa √ √   √   
UL49 essential 63 kDa √ √   √   
UL57 essential 136 kDa √ √     √ 
UL92 essential 33 kDa √ √   √   
UL95 essential 59 kDa √ √   √   
UL34 essential 45 kDa √ √   √   
UL87 essential 104 kDa √ √   √   
UL48 augmenting 247 kDa √ √   √   
UL96 essential 14 kDa √         
UL94 essential 38 kDa √         
UL93 essential 65 kDa √         
UL114 augmenting 28 kDa √         
UL47 augmenting 108 kDa √         
UL30 augmenting 12 kDa           
 
Table 1.1.  Selected Uncharacterized HCMV Essential and Augmenting Genes 
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Chapter 2: 
 
 
Characterization of HCMV novel essential protein 
pUL79 and determine its roles in viral late gene 
expression 
 
 
This chapter contains data published in the following publication 
 
Perng YC, Qian Z, Fehr AR, Xuan B, Yu D. (2011) The human 
cytomegalovirus gene UL79 is required for the accumulation of late viral 
transcripts.  Journal of Virology May;85(10):4841-52. 
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ABSTRACT 
     In this chapter, we adopted a conditional protein genetic approach to characterize the role 
of the human cytomegalovirus (HCMV) gene UL79 during virus infection.  We constructed 
ADddUL79, a recombinant HCMV in which the annotated UL79 open reading frame (ORF) 
was tagged with the destabilization domain of a highly unstable variant of the human 
FKBP12 protein (ddFKBP). The ddFKBP domain targets the tagged protein for rapid 
proteasomal degradation, but the synthetic ligand Shield-1 can stabilize ddFKBP, allowing 
accumulation of the tagged protein.  ADddUL79 failed to replicate without Shield-1, but it 
grew at wild-type levels with Shield-1 or in human foreskin fibroblasts overexpressing 
hemagglutinin (HA)-tagged UL79 (HF-UL79HA cells), indicating an essential role of UL79 
and the effectiveness of this approach.  Without Shield-1, representative immediate-early and 
early viral proteins as well as viral DNA accumulated normally, but late transcripts and 
proteins were markedly reduced.  UL79 was transcribed with early-late kinetics, which was 
also regulated via a positive-feedback loop.  Using HF-UL79HA cells, we found that the 
UL79 protein localized to viral replication compartments during HCMV infection.  Finally, 
we created a second UL79 mutant virus (ADinUL79stop) in which the UL79 ORF was 
disrupted by a stop codon mutation and found that ADinUL79stop phenocopied ADddUL79 
under the destabilizing condition.  Taking these results together, we conclude that UL79 acts 
after viral DNA replication to promote the accumulation of late viral transcripts.  Importantly, 
the comparative analysis of ADddUL79 and ADinUL79stop viruses provide additional proof 
for the power of the protein stability-based conditional approach to dissect the role of viral 
factors in HCMV biology. 
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INTRODUCTION 
     Human cytomegalovirus (HCMV) is the prototypical betaherpesvirus and a ubiquitous 
opportunistic pathogen that infects the majority of the world's population.  Upon primary 
infection, HCMV establishes a lifelong persistent and latent/recurrent infection in a host(8).  
Even though HCMV infection is usually asymptomatic in healthy individuals, it is a 
significant source of severe disease in immunocompromised adults, such as AIDS patients 
and transplant recipients.  Importantly, HCMV is the leading infectious cause of birth defects 
in newborns.  Additionally, there is evidence that HCMV is a possible risk factor in the 
development of vascular disease, such as atherosclerosis, transplant vascular sclerosis, and 
coronary restenosis after angioplasty surgery(15, 24, 31, 35, 40, 42, 57).  To acquire a 
comprehensive understanding of HCMV biology and facilitate the effort to develop effective 
therapeutics to combat disease caused by HCMV, it is imperative to dissect the roles of 
previously uncharacterized viral genes in both acute and latent infections of this virus. 
     During lytic infection, HCMV genes are expressed in a highly ordered temporal cascade.  
Viral transcripts accumulate in three different kinetic classes, namely, immediate early (IE), 
early, and late.  The HCMV major IE (MIE) genes UL123 (IE1) and UL122 (IE2) play a 
critical role in predisposing the cellular environment to infection, and they act as 
transactivators to induce transcription of early genes.  Many early genes encode proteins 
involved in viral DNA replication or predisposing the cellular environment to infection(17, 
18, 29, 30).  The transcript accumulation of early genes is independent of viral DNA 
replication; however, the continued accumulation of a subset of genes (i.e., early-late) is 
enhanced by the onset of viral DNA replication(41).  Following viral DNA replication, late 
viral genes that mainly encode structural proteins start to transcribe, ultimately leading to the 
assembly and release of infectious particles.  Although late gene transcription is tightly 
coupled to viral DNA replication, the underlying mechanism is poorly understood. 
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     HCMV contains a 240-kb double-stranded DNA genome that contains at least 166 
putative open reading frames (ORFs) and several microRNAs(7, 15, 17-19, 29, 30).  
Previously we and others have used genome-wide mutagenic approaches to classify the entire 
set of HCMV genes that encode annotated ORFs into three functional categories(9, 54), and 
we found that about 40 genes are essential for the HCMV laboratory strain AD169 to 
replicate in human fibroblasts.  Many of the HCMV genes have not been experimentally 
characterized and lack homologues with known functions in other herpesviruses(33), and 
their functions therefore remain elusive.  With the advent of the infectious bacterial artificial 
chromosome clone-based system for HCMV (BAC-HCMV)(4, 55), the functions of many 
HCMV genes have started to be elucidated.  However, defining the role of essential genes 
remains challenging because of a paucity of a reliable system to propagate null mutant 
viruses.  The conventional complementation approach, namely, the use of cells expressing a 
viral gene in trans to support the growth of the null mutant, has been reported for only a few 
essential HCMV genes(33).  To overcome this technical hurdle, we and others have recently 
adopted a conditional approach(3) to facilitate the analysis of proteins critical to viral growth 
and pathogenesis(14, 37).  This approach takes advantage of a mutant variant of the human 
FKBP12 protein that is highly unstable and rapidly degraded when expressed in mammalian 
cells(3).  Using this method, a recombinant virus in which a viral ORF of interest is tagged 
with the destabilization domain of this FKBP variant (ddFKBP) that confers rapid instability 
can be constructed.  The addition of the cell-permeable, synthetic ligand Shield-1 stabilizes 
the fusion protein, allowing propagation of the recombinant virus.  Upon withdrawal of 
Shield-1, ddFKBP targets the fusion protein for rapid degradation, thus allowing the study of 
the virus infection in the absence of the protein of interest.  ddFKBP tagging offers a robust 
genetic tool to study the role of viral genes, particularly the ones that are essential for HCMV 
infection. 
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     In this chapter, we characterized the role of viral gene UL79 in HCMV replication.  UL79 
was previously classified as being essential for HCMV replication in fibroblasts by two large-
scale mutagenic analyses(9, 54).  To define its function during virus replication, we 
engineered a recombinant HCMV virus (ADddUL79) in which the annotated UL79 ORF was 
tagged with ddFKBP.  Using the ddFKBP approach, we found that UL79 was critical for the 
accumulation of late viral transcripts but not viral DNA synthesis.  This phenotype was 
further validated by our analysis of a second UL79 mutant virus in which the UL79 ORF was 
disrupted by a stop codon mutation.  Furthermore, UL79 was expressed with early-late 
kinetics, was regulated by a positive-feedback loop, and primarily localized to viral nuclear 
replication compartments during infection. 
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MATERIALS AND METHODS 
Plasmids, antibodies, and chemicals.  pYD-C169 is a retroviral vector derived from pRetro-
EBNA(23).  It was created by inserting a PCR fragment containing the sequence of the UL79 
ORF along with a C-terminal hemagglutinin (HA) tag into the multiple cloning site of 
pRetro-EBNA.  pYD-C630 was derived from pGalK(47) and carried the 110-amino-acid 
destabilization domain of the human FKBP12 protein variant that contained the F36V and 
L106P destabilizing mutations (ddFKBP)(3).  In this vector, ddFKBP was followed by a 
GalK/kanamycin dual expression cassette that was flanked by the Flp recognition target 
(FRT) sequence. 
     The primary antibodies used in this study included anti-β-actin (clone AC15; Abcam), 
anti-pUL44 (clone 10D8; Virusys), anti-IE2 (MAB8140; Chemicon), anti-HA (H6908; 
Sigma), anti-PCNA (clone F-2; Santa Cruz), and anti-FKBP12 (8/FKBP12; BD Biosciences). 
Other primary antibodies used in this study were anti-IE1(43), anti-pp28(39), anti-UL38(39), 
anti-UL69(25), anti-pp71(6), and anti-pp150 (all generous gifts from Thomas Shenk, 
Princeton University).  Secondary antibodies used for immunoblotting were horseradish 
peroxidase (HRP)-conjugated goat anti-mouse IgG and HRP-conjugated goat anti-rabbit IgG 
(Jackson Laboratory).  The secondary antibodies used for immunofluorescence were Alexa 
Fluor 568-conjugated goat anti-rabbit IgG and Alexa Fluor 488-conjugated goat anti-mouse 
IgG (Invitrogen-Molecular Probes). 
     The synthetic chemical ligand Shield-1 (Shld1) that was used to regulate the stability of 
ddFKBP-tagged proteins was purchased from Cheminpharma (Farmington, CT). 
 
Cells and viruses.  Primary human newborn foreskin fibroblasts (HFFs) and embryonic lung 
fibroblasts (MRC5) were propagated in Dulbecco modified Eagle medium (DMEM) 
supplemented with 10% fetal calf serum, nonessential amino acids, sodium pyruvate, and 
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penicillin-streptomycin.  To create HFFs expressing the HA-tagged UL79 (HF-UL79HA 
cells) or empty vector (HF-vector cells), retrovirus stocks were prepared from Phoenix-
Ampho cells(23) that were transfected with the retroviral vector pYD-C169 or pRetro-
EBNA, respectively.  HFFs were transduced with retrovirus three times and then allowed to 
recover for 72 h to generate a pool of cells expressing the protein of interest. 
     Various BAC-HCMV clones were constructed to reconstitute recombinant HCMV 
viruses.  Two BAC-HCMV clones, pAD/Cre and pAD-GFP, were used as the parental clones 
to produce wild-type viruses ADwt.2 and ADwt, respectively.  pAD/Cre carries the full-
length genome of HCMV strain AD169, and pAD-GFP is identical to pAD/Cre except that it 
contains a simian virus 40 (SV40) early promoter-driven green fluorescent protein (GFP) 
gene in place of the viral US4-US6 region(43, 55).  All other recombinant BAC clones were 
constructed by using a linear recombination protocol in the bacterial strain SW105 that 
contained an arabinose-inducible Flp gene for the transient expression of Flp 
recombinase(47).  To create a BAC clone in which the UL79 ORF was tagged with the 
ddFKBP sequence at its N terminus, a cassette that contained the ddFKBP sequence followed 
by the GalK/kanamycin dual marker was amplified by PCR from pYD-C630 with a pair of 
70-bp primers.  The 5’-terminal 50-bp sequences of these primers were homologous to the 
viral sequence immediately upstream or downstream of the N terminus of the UL79 ORF (5’-
TCGTCCATCGTCATTGTCGTCACCGTCGCT 
ACCCGCTCACCGAGCGAACGATGGGAGTGCAGGTGGAAACCATC-3’ and 5’-
TTGCCCGTGCGGACCCGCGGGACGGCGGGGTTCTCTTCGTCGCGGGCCATGCTGG
AGCCACCGCGGGAAGTTC-3’).  The cassette was recombined into pAD-GFP at the N 
terminus of the UL79 ORF by linear recombination, and the resulting transformants were 
selected on kanamycin-containing LB plates to identify clones carrying the marker cassette.  
As the GalK/kanamycin marker was also flanked by FRT sites, it was then removed from the 
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BAC by adding arabinose to a fresh culture to induce Flp recombinase expression and plating 
for isolation of single colonies lacking kanamycin resistance.  Therefore, the final clone 
(ADddUL79) contained the ddFKBP sequence along with a small FRT site fused in frame at 
the N terminus of UL79 (see Figure 2.1A).  To create a BAC clone in which the UL79 ORF 
was prematurely terminated by a stop codon, a cassette that contained a stop codon followed 
by the FRT-bracketed GalK/kanamycin dual marker was amplified by PCR from pYD-C649 
with a pair of 70-bp primers.  The 5’-terminal 50-bp sequences of these primers were 
homologous to the viral sequence immediately upstream or downstream of the 5th amino acid 
of the UL79 ORF (5’-
GTCGTCACCGTCGCTACCCGCTCACCGAGCGAACGATGATGGCCCGCGA 
CTGATCACTATAGGGCGAATTGGGTA-3’ and 5’-GTAAAGGAGAATTTGCCC 
GTGCGGACCCGCGGGA CGGCGGGGTTCTCTTCAGGGAACAAAAGCTGGA 
GCTCC-3’).  The cassette was recombined into the UL79 ORF of pAD-GFP, and the 
GalK/kanamycin marker was then removed by Flp/FRT recombination as described above 
(see Figure 2.7A).  The final clone (ADinUL79stop) contained a stop codon along with a small 
FRT site inserted in frame at the 6th amino acid codon of the UL79 ORF.  All recombinant 
BACs were verified by restriction digestion, PCR, and direct sequencing analysis. 
     To reconstitute virus, 2 µg of the BAC-HCMV DNA and 1 µg of the pp71 expression 
plasmid were transfected into HFFs or HF-UL79HA cells by electroporation(55), and the 
culture medium was changed 24 h later.  For reconstitution of ddFKBP-tagged virus, the 
synthetic chemical ligand Shield-1 was added every 48 h to maintain the concentration at 1 
µM.  The recombinant virus was harvested by collecting cell-free culture supernatant when 
the entire monolayer of infected cells was lysed.  Virus was amplified by collecting cell-free 
culture supernatant from HFFs infected at a multiplicity of infection (MOI) of 0.01 in the 
presence of Shield-1.  To remove any residual Shield-1, virus-containing culture supernatants 
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were then purified by ultracentrifugation through a 20% D-sorbitol cushion at an average 
relative centrifugal force of 53,000 × g for 1 h, resuspended in DMEM with 10% fetal calf 
serum, and saved as viral stocks.  HCMV titers were determined by 50% tissue culture 
infectious dose (TCID50) assay.  For ddFKBP-tagged virus, the titer was determined in 
duplicate in HFFs in the presence of 1 µM Shield-1 (unless indicated otherwise).  For 
ADinUL79stop virus, the titer was determined in duplicate in HF-UL79HA cells. 
 
Analysis of viral growth kinetics.  HFFs, HF-vector cells, or HF-UL79HA cells were 
seeded in 12-well plates overnight to produce a subconfluent monolayer.  Cells were then 
inoculated with recombinant HCMV viruses for 1 h at an MOI of 0.1 for multistep growth 
analysis or an MOI of 3 for single-step growth analysis.  The inoculum was removed, the 
infected monolayers were rinsed with phosphate-buffered saline, and infected cells were 
cultured in medium in the presence or absence of Shield-1 (1 µM).  To infect cells with virus 
in the presence of ligand Shield-1, the ligand was added every 48 h to maintain its 
concentration.  At various times postinfection, cell-free virus was collected by harvesting the 
medium from infected cultures, and the titers of the virus were determined by TCID50 assay. 
 
DNA and RNA analysis.  Intracellular viral DNA was measured by quantitative PCR 
(qPCR) as previously described(38).  HCMV-infected cells were collected at various times 
postinfection, resuspended in lysis buffer (200 mM NaCl, 20 mM Tris [pH 8.0], 50 mM 
EDTA, 0.2 mg/ml proteinase K, 1% sodium dodecyl sulfate [SDS]), and incubated at 55°C 
overnight. DNA was extracted with phenol-chloroform, treated with RNase A (100 µg/ml), 
extracted again with phenol-chloroform, precipitated with ethanol, and resuspended in 
nuclease-free water (Ambion).  Viral DNA was quantified by qPCR as previously described 
using a TaqMan probe (Applied Biosystems) and primers specific for the HCMV UL54 
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gene(38).  Cellular DNA was quantified with SYBR PCR master mix (Clontech) and a 
primer pair specific for the human β-actin gene as previously described(38).  The 
accumulation of viral DNA was normalized by dividing the number of UL54 gene 
equivalents by the number of β-actin gene equivalents.  The accumulation of wild-type viral 
DNA at 4 h postinfection (hpi) was arbitrarily set at 1. 
     Transcript accumulation was analyzed by reverse transcription coupled to qPCR (RT-
qPCR) as previously described(53).  Total RNA was extracted using the Trizol reagent 
(Invitrogen) and treated with the TURBO DNA-free reagent (Ambion) to remove genomic 
DNA contaminants.  cDNA was reverse transcribed with random hexamer primers using the 
high-capacity cDNA reverse transcription kit (Applied Biosystems).  For IE1, cDNA was 
quantified by qPCR using Maxima probe/Rox 2× qPCR master mix (Fermentas), and a 
TaqMan probe (Applied Biosystems) and a primer pair specific for IE1.  Alternatively, 
cDNA was quantified using SYBR Advantage qPCR premix (Clontech) and primer pairs 
specific for viral genes UL32, UL79, UL82, UL93-99, the ddFKBP sequence of ddFKBP-
UL79, or the GAPDH (glyceraldehyde-3-phosphate dehydrogenase) cellular gene(10, 32, 
48).  All of the primer pairs and TaqMan probes are listed in Table 2.1.  cDNA from infected 
cells was used to generate a standard curve for each gene examined. The standard curve was 
then used to calculate the relative amount of a specific transcript present in a sample. The 
amounts of IE1, UL32, UL79, UL82, and UL93-99 were normalized using GAPDH as an 
internal control. 
 
Protein analysis.  Protein accumulation and subcellular localization were determined by 
immunoblotting and immunofluorescence, respectively.  For immunoblotting, cells were 
washed with phosphate-buffered saline and lysed in the sodium dodecyl sulfate (SDS)-
containing sample buffer.  Virion proteins were prepared by purifying cell-free virions from 
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culture medium of infected cells by ultracentrifugation through a sorbitol cushion and 
resuspending the cells in SDS-containing sample buffer.  Proteins were resolved by 
electrophoresis on an SDS-containing polyacrylamide gel, transferred to a polyvinylidene 
difluoride (PVDF) membrane, hybridized with primary antibodies, reacted with the HRP-
conjugated secondary antibody, and visualized by SuperSignal West Pico chemiluminescent 
substrate (Thermo Scientific)(53). 
     For immunofluorescence, cells grown on glass coverslips were fixed in 2% 
paraformaldehyde, permeabilized with 0.1% Triton X-100 for 15 min, incubated with a 
primary antibody, and subsequently labeled with an Alexa Fluor 488- or 568-conjugated 
secondary antibody (Invitrogen-Molecular Probes).  Labeled cells were also counterstained 
with TO-PRO-3 (Invitrogen-Molecular Probes) to visualize the nuclei.  Finally, labeled cells 
were mounted on slides with Prolong Gold antifade reagent (Invitrogen-Molecular Probes).  
Images were captured using Zeiss LSM Image software with a Zeiss LSM 510 META 
confocal laser scanning microscope. 
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RESULTS 
Construction of a BAC-HCMV clone carrying the ddFKBP-tagged UL79 and 
propagation of recombinant virus.  The HCMV UL79 ORF has been reported to be 
essential for HCMV replication in fibroblasts(9, 54).  To study the function of UL79 in virus 
infection, we adopted a protein-based viral genetic approach(3, 14, 37).  We constructed a 
recombinant BAC-HCMV clone, pADddUL79, in which the annotated UL79 coding 
sequence was tagged with a 110-amino-acid destabilization domain derived from a mutant 
variant of the human FKBP protein (ddFKBP)(3) at its N terminus (Figure 2.1A).  This 
recombinant clone was derived from the parental BAC clone (pAD-GFP) which was also 
used to reconstitute wild-type virus (ADwt) in this study(55).  In cells infected with 
recombinant virus (ADddUL79) that was derived from pADddUL79, the ddFKBP-tagged 
UL79 protein was anticipated to be expressed but directed for rapid degradation by the 
ddFKBP tag.  However, the ddFKBP tag should be stabilized in the presence of the synthetic 
chemical ligand Shield-1, and therefore, the tagged protein should retain its activity.  This 
ddFKBP tagging approach offers some unique advantages for creating mutant viruses.  It 
abrogates protein products of essential genes during virus infection without the need for 
creating null mutant virus and complementing cell lines.  As only one virus stock is needed 
for the comparative study of HCMV infection in the presence or absence of a viral protein 
product, it eliminates the need for creating marker rescued virus and avoids the potential 
complication resulting from an altered particle-to-PFU ratio in mutant virus.  Finally, it 
provides evidence that it is the protein encoded by the tagged ORF and not other potential 
products derived from the UL79 locus that is important for viral replication. 
     Transfection of pADddUL79 into human foreskin fibroblasts (HFFs) did not result in any 
detectable productive viral infection when the cells were surveyed for 30 days.  However, 
when Shield-1 was added at a concentration of 1 µM, a cytopathic effect (CPE) was 
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observed, similar to that in transfection with wild-type pAD-GFP.  Recombinant virus 
ADddUL79 produced from pADddUL79 transfection was then amplified by infecting fresh 
HFFs in the presence of Shield-1, purified by ultracentrifugation, and resuspended in fresh 
medium to generate a virus stock.  To confirm that viral growth was dependent on the 
presence of Shield-1, HFFs were infected with ADddUL79 at an MOI of 3 with various 
concentrations of Shield-1.  Infectious culture supernatants were collected at 96 h 
postinfection (hpi), and the titer of cell-free virus was determined by TCID50 assay (Figure 
2.1B).  The rescue of ADddUL79 replication by Shield-1 was dose dependent.  While 
ADddUL79 failed to produce detectable progeny without Shield-1, its replication and CPE 
were indistinguishable from those of the wild-type virus with 1 µM Shield-1 (Figure 2.1B 
and C).  Our results suggest that Shield-1 efficiently regulates the replication of ADddUL79 
recombinant virus. 
     To provide additional proof that Shield-1 regulated ADddUL79 replication by controlling 
the stability of the ddFKBP-tagged UL79 protein, we wanted to examine the expression of 
the tagged protein in fibroblasts infected with ADddUL79.  Surprisingly, we could not detect 
the tagged protein during infection regardless of Shield-1 treatment using an anti-FKBP12 
antibody.  This was not due to the inability of the antibody to recognize the ddFKBP domain, 
because we have used the same antibody to detect other ddFKBP-tagged viral proteins 
(Figure 2.10).  Moreover, we were able to readily detect the ddUL79 protein from cells 
transfected with a plasmid overexpressing ddUL79 in the presence of Shield-1 using the anti-
FKBP12 antibody (data not shown).  Therefore, our inability to detect the tagged protein is 
likely the result of the low-level accumulation of the UL79 protein during HCMV infection.  
As an alternative approach to confirm that the UL79 ORF encoded a protein essential for 
HCMV growth, we tested the growth of ADddUL79 in UL79-overexpressing HFFs (HF-
UL79HA cells) that were made by transduction of retrovirus carrying the C-terminally HA-
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tagged UL79 ORF. HF-UL79HA cells expressed the tagged protein at the predicted size (35 
kDa) (Figure 2.1C).  In normal HFFs, ADddUL79 grew like wild-type virus did in the 
presence of Shield-1 but could not replicate without it.  In contrast, ADddUL79 virus could 
replicate in HF-UL79HA cells in the absence of Shield-1, producing virus titers similar to 
those of ADwt.  Therefore, the growth defect of ADddUL79 in the absence of Shield-1 is the 
direct result of the abrogation of UL79. 
 
UL79 is essential for HCMV replication.  To characterize the role of UL79 in HCMV 
replication, we first analyzed the growth kinetics of the ADddUL79 virus in HFFs.  For 
progeny virus collected at each time point, we determined the titer of virus in the presence 
and absence of Shield-1 to determine whether there were additional escape mutations 
acquired during the course of infection.  Under the multistep growth condition, ADddUL79 
replicated indistinguishably from ADwt in the presence of Shield-1.  However, without 
Shield-1, the production of ADddUL79 was almost undetectable by 12 days postinfection 
(dpi), whereas ADwt growth peaked and the titers reached 1 × 107 TCID50 units/ml (Figure 
2.1A).  It was noted that at 15 dpi in the absence of Shield-1, ADddUL79 started to produce 
very low levels of progeny that could be determined even in the absence of Shield-1.  We 
interpreted these results to mean that ADddUL79 might acquire spontaneous escape 
mutations after a prolonged period under nonpermissive conditions. 
     Next, we examined the single-step growth kinetics of ADddUL79 to determine whether 
the defect was dependent on the MOI.  At an MOI of 3 and in the absence of Shield-1, 
ADddUL79 produced almost no virus by 4 dpi and very low levels of progeny (<1 × 103 
TCID50 units/ml) by 6 dpi, while ADwt reached peak titers of 1 × 107 TCID50 units/ml 
(Figure 2.1A).  In contrast, Shield-1 treatment restored the growth of ADddUL79 to wild-
type levels.  The very low levels of ADddUL79 produced after 5 dpi in the absence of Shield-
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1 might be due to the slight leakiness of Shield-1 regulation of ddFKBP degradation(3).  It 
was unlikely that this low level of virus growth represented escape mutants because they 
could not establish a second round of infection without Shield-1, their titers did not increase 
over time, and their titers could not be measured without Shield-1. 
     Taken together, these data indicate that UL79 is essential for HCMV replication in 
cultured fibroblasts and that ddFKBP-mediated Shield-1 regulation allows for tight control of 
UL79 function during the virus infection cycle. 
 
UL79 is required for viral replication at late stages of infection.  To determine when 
UL79 is required during the viral replication cycle, we stabilized UL79 protein accumulation 
by Shield-1 at various time points and for different lengths of time in infected cells and then 
determined the impact of such temporal accumulation of UL79 proteins on virus production.  
To determine whether UL79 was required at early times, Shield-1 was added at the onset of 
virus infection but was removed from the medium at 24 or 48 hpi.  To determine whether 
UL79 was required at late times during infection, Shield-1 was added at 24 or 48 hpi.  In both 
experiments, the titers of virus in the supernatants of infected cells were determined at 120 
hpi (Figure 2.2B).  When we added Shield-1 as late as 48 hpi, ADddUL79 replication was 
indistinguishable from virus grown in the continuous presence of Shield-1.  In contrast, when 
Shield-1 was present for only the first 48 h during infection, almost no viral progeny were 
produced, similar to ADddUL79 infection in the complete absence of Shield-1.  Taken 
together, these data indicate that UL79 is required for viral replication during the late stages 
of viral infection. 
 
UL79 is required for late viral gene expression.  To determine which step of the viral 
replication cycle was compromised in the absence of UL79, we first examined the viral 
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protein accumulation profile in the absence of Shield-1.  The accumulation of viral 
immediate-early proteins (IE1-72 and IE2-86) or early/early-late proteins (UL38, UL44, 
UL69, and pp65) in cells infected with ADddUL79 was not affected (Figure 2.3 and data not 
shown). In contrast, the true late proteins, pp28, pp71, and pp150, accumulated at markedly 
reduced levels. 
     To determine whether the reduced late protein accumulation in ADddUL79 infection was 
the result of reduced viral late transcript accumulation, we analyzed the IE1 transcript 
(control) and late UL32 (pp150), UL82 (pp71), and coterminated UL93-99 transcripts by RT-
qPCR analysis (Figure 2.4)(10, 32, 48).  All transcripts detected were specific and were not 
the result of genomic DNA contamination, as mock-infected cells and qPCR reactions done 
in the absence of reverse transcriptase failed to produce any products (data not shown).  At 24 
hpi, late transcripts were barely detectable, whereas the IE1 transcript accumulated to a high 
level (data not shown).  Importantly, stabilization of UL79 by Shield-1 had no substantial 
effects on viral transcript accumulation at this time point (Figure 2.4), consistent with the 
observation that UL79 was not required at early times of infection (Figure 2.2B).  At 72 hpi, 
even though degradation of UL79 had only a small effect on IE1 transcript accumulation, as 
the viral DNA synthesis inhibitor phosphonoacetic acid (PAA) did(10), it reduced the 
accumulation of late transcripts almost as markedly as PAA did.  The levels of late UL32, 
UL82, and UL93-99 transcripts when UL79 was absent were 7-, 27-, and 13-fold lower than 
the levels when UL79 was present, respectively (Figure 2.4).  Together, our results indicate 
that UL79 has minimal effect on viral immediate-early and early gene expression but is 
critical for the accumulation of late viral transcripts and proteins. 
 
UL79 is dispensable for viral DNA replication.  As viral late gene expression is dependent 
on viral DNA replication, it was possible that the defect in late gene expression in the 
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absence of UL79 was due to a defect in viral DNA replication.  Thus, we examined viral 
DNA synthesis in the absence of Shield-1 (Figure 2.5A).  Surprisingly, the kinetics of viral 
DNA replication during ADddUL79 infection in cells in the absence of Shield-1 was 
indistinguishable from that of infection of cells in the presence of Shield-1.  To confirm that 
Shield-1 withdrawal was effective, supernatants from infected culture were collected at 72 
hpi and measured for virus production (Figure 2.5B).  Infected cells in the absence of Shield-
1 produced no detectable virus, indicating that UL79 function was indeed abrogated in these 
cells.  Therefore, we conclude that UL79 acts after viral DNA replication and is specifically 
required for the accumulation of late viral transcripts. 
 
The UL79 transcript is expressed with early-late kinetics and is regulated by a positive-
feedback loop.  To determine the kinetic class of UL79 expression, we analyzed the UL79 
transcript accumulation in fibroblasts infected with ADddUL79 by RT-qPCR (Figure 2.6A).  
When the UL79 protein was stabilized, the UL79 transcript accumulated abundantly at late 
times of infection, and its level at 72 hpi was 5-fold higher than the level at 24 hpi.  The 
UL79 transcript level was markedly reduced at 72 hpi when infected cells were treated with 
PAA, indicating that its transcript accumulation was augmented by viral DNA replication.  
However, in the presence of PAA, the accumulation of UL79 transcript was not completely 
inhibited, as the UL79 transcript levels increased almost 3-fold from 24 to 72 hpi.  Therefore, 
as the accumulation of UL79 transcript is markedly enhanced by, but not completely 
dependent on viral DNA synthesis, our data suggest that UL79 is an early-late HCMV gene.  
However, in the present study, we cannot rule out the possibility that more than one transcript 
emanates from the UL79 locus and that our result reflects the combined expression profile of 
these transcripts rather than individual species. 
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     Surprisingly, when UL79 proteins were destabilized, the level of UL79 transcript was 
drastically reduced in infected cells at 72 hpi (Figure 2.6A).  This suggests a positive-
feedback loop for UL79 expression which in turn amplifies the expression of late viral genes.  
To provide additional evidence for this autoregulation of UL79 transcription by its protein 
products, we tested whether we could enhance endogenous UL79 transcription during 
infection of UL79 recombinant virus by providing the UL79 protein in trans.  We infected 
HFFs expressing the HA-tagged UL79 (HF-UL79HA cells) or empty vector (HF-vector cells) 
with ADddUL79 in the absence of Shield-1.  This experimental system allowed us to 
uncouple the UL79 protein accumulation (provided by HF-UL79HA cells) and endogenous 
UL79 transcript accumulation (from the viral genome).  The endogenous UL79 transcription 
was analyzed by RT-qPCR using a primer pair specific to the ddFKBP sequence.  We found 
that the accumulation of ddFKBP-UL79 transcripts in infected HF-UL79HA cells markedly 
increased at 72 hpi relative to that in infected HF-vector cells.  This indicates that, as 
anticipated, the UL79 protein enhances the transcription from the UL79 gene locus (Figure 
2.6B).  Together, these results suggest that efficient transcription of UL79 is positively 
regulated by both viral DNA replication and its own protein products. 
 
A UL79 stop codon mutant virus has the same defect as ADddUL79.  To provide 
additional proof that the defect of ADddUL79 was the direct result of the loss of UL79 
function, we created a second UL79 mutant virus, ADinUL79stop.  In this recombinant virus, 
we inserted a stop codon at residue Glu6 of the UL79 ORF to abrogate the expression of 
UL79 protein products (Figure 2.7A).  The ADinUL79stop virus could be reconstituted only 
from transfection of the BAC clone in HF-UL79HA cells, not by transfection in normal HFFs 
or HF-vector cells.  The titer of reconstituted mutant virus was comparable to that of wild-
type virus (data not shown), and it replicated efficiently in HF-UL79HA cells but completely 
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failed to grow in HF-vector cells (Figure 2.7B).  These results indicated that loss of UL79 
function was solely responsible for the growth defect of ADinUL79stop.  Importantly, cells 
infected with ADinUL79stop synthesized viral DNA at wild-type levels (Figure 2.7C) and 
accumulated the products of IE genes (IE1-72 and IE2-86) and early genes (pUL38 and 
pUL44) efficiently but had a marked defect in accumulation of viral late proteins (pp71 and 
pp28) during infection (Figure 2.7D).  Therefore, the defect of ADinUL79stop phenocopied 
that of ADddUL79 under Shield-1 withdrawal, and our results provide further validation for 
the power of the protein stability-based conditional approach to dissect the role of viral 
factors in HCMV biology. 
 
The HA-tagged UL79 protein is primarily nuclear and localizes in replication 
compartments during virus infection.  As UL79 is required for the accumulation of late 
viral transcripts, it is possible that it is a nuclear protein involved in the regulation of viral 
late gene transcription.  We first examined the intracellular distribution of UL79 expressed 
alone to determine its ability to localize into the nucleus in the absence of any other viral 
factors.  We used HF-UL79HA cells because there was no antibody specific to UL79 
available and because the tagged UL79 was fully functional to complement UL79-deficient 
virus (Figure 2.1C).  While no appreciable HA staining was present in normal HFFs, the 
staining was readily observed in HF-UL79HA cells, predominantly localizing within the 
nuclei, suggesting that UL79 proteins are primarily nuclear (Figure 2.8A).  Next we 
determined whether the UL79 proteins localized to any virus-induced intracellular structures 
during infection, particularly replication compartments.  These organized intranuclear viral 
structures are sites where sets of viral proteins (e.g., pUL44, pUL57, pUL117, and IE2)(1, 36, 
38) and cellular proteins (e.g., p53, Nbs1, and Rad50)(12, 26) are recruited to, and viral 
activities, including viral DNA synthesis, late gene transcription, and DNA packaging, take 
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place.  To test our hypothesis, we examined the localization of the HA-tagged UL79 proteins 
expressed from HF-UL79HA cells that were infected with HCMV, as we were not able to 
detect tagged UL79 proteins expressed from the endogenous locus of the viral genome during 
infection (data not shown).  The tagged UL79 proteins formed large intranuclear domains 
which colocalized with pUL44, the virus-encoded DNA polymerase accessory protein that 
has been used as a marker for replication compartments(36, 38) (Figure 2.8A), indicating that 
a major fraction of HA-tagged UL79 proteins is localized in replication compartments.  
Importantly, the formation of UL79-containing large intracellular domains appeared to occur 
at late times during infection (Figure 2.8B), providing additional evidence that UL79 
functions at late times to regulate gene expression. 
     We noted that the anti-HA antibody also appeared to generate low-level cytoplasmic 
staining in some normal HFFs that were infected with HCMV, even though this staining 
intensified in infected cells that expressed the tagged UL79 protein (Figure 2.8A).  This 
cytoplasmic staining colocalized with pp28-containing viral assembly centers (data not 
shown).  Nonetheless, we decided not to pursue this further, as we could not rule out the 
possibility that the cytoplasmic HA staining represents the nonspecific recognition of 
assembly centers by anti-HA antibody. 
 
The UL79 protein is not detected in HCMV virions.  A proteomics study has previously 
shown that a single UL79-derived peptide can be detected in the HCMV virions only by the 
sensitive Fourier transform ion cyclotron resonance (FTICR) mass spectrometry, not by the 
more traditional liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis, 
suggesting that this peptide may represent a nonspecific contaminant(46).  To determine 
whether the UL79 protein is a tegument protein, we infected HF-UL79HA cells or HF-vector 
cells with ADddUL79 in the presence or absence of Shield-1.  We then harvested 
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supernatants from infected cells at 96 hpi and partially purified cell-free virions by 
ultracentrifugation through a sorbitol cushion.  These virion samples appeared to be largely 
free of contamination of cellular debris, as they did not contain detectable amounts of the 
viral IE1 protein or the cellular PCNA protein (Figure 2.9).  On the other hand, the major 
capsid protein (MCP) was readily detected, and importantly, pUL69, a protein that is present 
in the tegument and dense bodies in very small amounts(46, 50), could also be detected in the 
virion samples (Figure 2.9). Under these conditions, however, we could not detect the HA-
tagged UL79 protein in the virion samples, even though it was readily detectable in total 
lysate of infected HF-UL79HA cells.  Thus, the UL79 protein is unlikely to be a major 
component of the HCMV virion. This was consistent with the result that UL79 appeared to 
be required only at late stages (i.e., after 48 hpi) (Figure 2.2B) and suggested the important 
role of the newly synthesized UL79 protein in promoting the HCMV lytic infection cycle.  
Collectively, our data indicate that UL79 plays a key role at late times after viral DNA 
replication to regulate the accumulation of late viral transcripts. 
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DISCUSSION 
In this study, we applied the ddFKBP-mediated, Shield-1-regulated protein genetic 
approach(3) to investigate the role of viral gene UL79 during HCMV replication.  Moreover, 
we also compared the effectiveness of this approach to the more traditional viral genetic 
approach by creating and analyzing the second UL79 mutant virus in which the UL79 ORF 
was disrupted by a stop codon mutation (Figure 7).  This comparative analysis provides 
additional proof for the power of the protein stability-based conditional approach to dissect 
the role of viral factors in HCMV biology.  Our work represents one of the few studies that 
take advantage of this powerful approach to define viral gene functions in HCMV 
biology(14, 37).  Shield-1 regulation of ddFKBP-tagged UL79 is robust, reversible, and 
precisely controlled and validates the role of UL79 as an essential HCMV gene (Figures 2.1 
and 2.2).  Interestingly, we could not detect ddFKBP-tagged UL79 protein in cells infected 
with ADddUL79 even with Shield-1 using an anti-FKBP12 antibody.   Nonetheless, the full 
complementation of ADddUL79 in the absence of Shield-1 by HFFs overexpressing UL79 
provided additional evidence that the defect of ADddUL79 was the direct result of UL79 
depletion (Figure 2.1C).  Our inability to detect the endogenous UL79 proteins during 
infection is likely due to either their extremely low levels of expression or their unstable 
nature, similar to other HCMV proteins such as pUL21a(11).  Notably, the accumulation of 
the HA-tagged UL79 protein overexpressed from transduced HFFs was also reduced during 
infection relative to that in mock-infected cells, suggesting that the turnover of UL79 proteins 
may be enhanced during infection (Figure 2.1C).  A more sensitive antibody or assay will 
need to be developed in order to detect and characterize endogenous UL79 proteins during 
HCMV infection. 
     Our systematic dissection of ADddUL79 infection in the absence of Shield-1 allowed us 
to define the stage of the infection cycle where UL79 functioned. Shield-1-dependent rapid 
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degradation/stabilization of ddFKBP-tagged proteins(3) gave us a tool to define the 
requirement of UL79 in HCMV infection in a nearly real-time manner (Figure 2.2B).  
Treating infected cells with Shield-1 for the first 48 hpi could not rescue the growth of 
recombinant virus, whereas adding Shield-1 at late times, even at 48 hpi, fully restored its 
growth (Figure 2.2), suggesting that UL79 was required at late stages of HCMV infection.  
Consistent with the timing of its involvement in virus infection, UL79 was expressed with 
early-late kinetics (Figure 2.6) and localized into viral replication compartments where viral 
DNA replication and late gene transcription took place (Figure 2.8).  These spatial and 
temporal characteristics of UL79 support its role in regulating the accumulation of viral late 
gene products at transcript levels (Figure 2.3, 2.4, and 2.7). 
     Depletion of UL79 during HCMV infection was able to uncouple viral DNA synthesis and 
viral late gene expression, indicating that the former is not sufficient to promote the latter 
(Figure 2.4 and 2.5).  For many DNA viruses, the temporal regulation of viral gene 
expression is a common feature of their lytic infection.  For simian virus 40, the large T 
antigen plays an essential role in the activation of viral promoters(5, 21), and viral DNA 
replication attenuates in trans the repressor of viral late promoters(49, 58).  For adenovirus, 
both viral trans-acting factors(16, 34) and viral DNA replication(44, 45) are required for its 
late gene expression.  Viral DNA replication facilitates late gene expression directly(44) or 
indirectly by promoting the expression of viral trans-acting factors(16) or recruitment of 
cellular transcription factors to late promoters(45). 
     For herpesviruses, viral late gene expression has been studied mostly with herpes simplex 
virus (HSV) and murine gammaherpesvirus 68 (MHV-68).  In HSV, DNA replication is 
required in cis for activity of late promoters(20, 28).  HSV proteins, including ICP4, ICP8, 
and ICP27, are necessary for efficient expression of late genes by interacting with the general 
transcription machinery(13, 22, 46), and they facilitate the assembly of transcription 
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preinitiation complexes(46, 56).  In MHV-68, both viral DNA replication (12) and four viral 
proteins, ORF18, ORF24, ORF30, and ORF34, are required for late gene expression(2, 51, 
52).  HCMV UL79, UL87, and UL95 share sequence homology with ORF18, ORF24, and 
ORF34, respectively, while ORF30 is conserved only in gamma-herpesviruses(2, 51, 52).  
Both UL79 and ORF18 are dispensable for viral DNA replication but are required for the 
accumulation of viral late gene products (Figures 2.4 and 2.5)(2), and UL79 also localizes to 
viral replication compartments (Figure 2.8).  However, UL79 shares only 28% amino acid 
identity to ORF18(2) and is transcribed with early-late kinetics (Figure 2.6), whereas ORF18 
was identified as an early gene(27).  This body of evidence suggests that a general regulatory 
principle of late viral gene expression is conserved across the herpesvirus family, but the 
precise mechanism may be unique to each herpesvirus. 
     How does UL79 regulate late viral gene expression? Three possible mechanisms are 
responsible for its activity.  It is possible that UL79 may modulate the initiation of late viral 
gene transcription(2).  It may act as a transcription activator, a function reminiscent of 
ORF18.  However, as in silico analysis did not reveal any significant homology of UL79 to 
known transcription factors or conserved DNA binding motif, UL79 may also stimulate late 
gene transcription by activating other transcriptional factors or dissociating repressors from 
late gene promoters.  Alternatively, UL79 may be involved in regulation of chromatin 
structures of replicating viral genomes, which may in turn facilitate late viral gene 
expression.  Finally, it is also possible that UL79 may promote the accumulation of late 
transcripts by maintaining their stability.  In any event, the temporal expression (i.e., early-
late kinetics) of UL79 may be partially responsible for its involvement in the accumulation of 
only the late transcripts and not the early transcripts.  The precise mechanism for how UL79 
selectively promotes viral late transcripts will be a key question to address in future study. 
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     How is the expression of UL79 regulated during HCMV infection?  UL79 is expressed 
with early-late kinetics; its transcripts accumulate even when viral DNA synthesis is 
inhibited, but the accumulation is markedly enhanced upon viral DNA synthesis (Figure 2.6).  
Importantly, the efficient accumulation of UL79 transcripts also requires the accumulation of 
UL79 proteins themselves and is regulated by a positive-feedback loop (Figure 2.6).  
Therefore, low-level UL79 expression appears to occur independently of viral DNA 
replication.  Viral DNA replication may increase the copy number of DNA templates for 
UL79 transcription.  Perhaps more importantly, any stimulatory effect of viral DNA 
replication on UL79 expression is further amplified via this positive-feedback loop.  
Therefore, it is sensible to speculate that viral DNA replication acts in cis and UL79 proteins 
function in trans to promote their own expression. 
     In conclusion, we have identified UL79 as a key viral factor bridging viral DNA 
replication and late gene expression during HCMV infection.  We are investigating potential 
interactions of UL79 with cellular proteins or other viral proteins to define its mechanism 
during HCMV infection. 
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FIGURES 
 
Figure 2.1 (A) Schematic diagram for creating recombinant virus ADddUL79 and applying a 
destabilization domain (ddFKBP)-mediated protein stability-based approach to regulate gene 
function.  ADddUL79 carried the UL79 ORF that was tagged at its N terminus with ddFKBP 
(indicated by gray box) and expressed the ddFKBP-UL79 fusion protein.  Without the small-
molecule ligand Shield-1 (Shld1), ddFKBP should direct the entire fusion protein for rapid 
degradation, thus effectively depleting UL79 proteins during infection.  However, Shield-1 
should bind to ddFKBP, protect the fusion protein from degradation, and maintain the 
accumulation of the UL79 proteins, thus allowing productive virus replication.  BAC, 
bacterial artificial chromosome.  (B) Dose-dependent regulation of ADddUL79 replication by 
Shield-1. Human foreskin fibroblasts (HFFs) were infected with ADddUL79 at a multiplicity 
of infection (MOI) of 3 in the presence of various concentrations of Shield-1 (as indicated).  
At 96 h postinfection (hpi), supernatants of infected cells were collected and analyzed for the 
pathic effect (CPE) was observed, similar to that in transfec-
tion with wild-type pAD-GFP. Recombinant virus ADddUL79
produced from pADddUL79 transfection was then amplified
by infecting fresh HFFs i the presence of Shield-1, purified by
ultracentrifugation, and resuspended in fresh medium to gen-
erate a virus stock. To confirm that viral growth was dep ndent
on the presence of Shield-1, HFFs were infected with
ADddUL79 at an MOI of 3 with various concentrations of
Shield-1. Infectious culture supernatants were collected at 96 h
postinfection (hpi), and the titer of cell-free virus was deter-
mined by TCID50 assay (Fig. 1B). The rescue of ADddUL79
replication by Shield-1 was dose dependent. While ADddUL79
failed to produce detectable progeny without Shield-1, its rep-
lication and CPE were indistinguishable from those of the
wild-type virus with 1 !M Shield-1 (Fig. 1B and C). Our results
suggest that Shield-1 efficiently regulates the replication of
ADddUL79 recombinant virus.
To provide additional proof that Shield-1 regulated
ADddUL79 replication by controlling the stability of the
ddFKBP-tagged UL79 protein, we wanted to examine the ex-
pression of the tagged protein in fibroblasts infected with
ADddUL79. Surprisingly, we could not detect the tagged pro-
tein during infection regardless of Shield-1 treatment using an
anti-FKBP12 antibody. This was not due to the inability of the
antibody to recognize the ddFKBP domain, because we have
used the same antibody to detect other ddFKBP-tagged viral
proteins (data not shown). Moreover, we were able to readily
detect the ddUL79 protein from cells transfected with a plas-
mid overexpressing ddUL79 in the presence of Shield-1 using
the anti-FKBP12 antibody (data not shown). Therefore, our
inability to detect the tagged protein is likely the result of the
low-level accumulation of the UL79 protein during HCMV
infection. As an alternative approach to confirm that the UL79
ORF encoded a protein essential for HCMV growth, we tested
the growth of ADddUL79 in UL79-overexpressing HFFs (HF-
UL79HA cells) that were made by transduction of retrovirus
carrying the C-terminally HA-tagged UL79 ORF. HF-
UL79HA cells expressed the tagged protein at the predicted
size (35 kDa) (Fig. 1C). In normal HFFs, ADddUL79 grew like
wild-type virus did in the presence of Shield-1 but could not
replicate without it. In contrast, ADddUL79 virus could repli-
cate in HF-UL79HA cells in the absence of Shield-1, produc-
ing virus titers similar to those of ADwt. Therefore, the growth
FIG. 1. (A) Schematic diagram for creating recombinant virus ADddUL79 and applying a destabilization domain (ddFKBP)-mediated protein
stability-based approach to regulate gene function. ADddUL79 carried the UL79 ORF that was tagged at its N terminus with ddFKBP (indicated
by gray box) and expressed the ddFKBP-UL79 fusion protein. Without the small-molecule ligand Shield-1 (Shld1), ddFKBP should direct the
entire fusion protein for rapid degradation, thus effectively depleting UL79 proteins during infection. However, Shield-1 should bind to ddFKBP,
protect the fusion protein fr m egradation, and maintain the accumulation of the UL79 proteins, thus allowing productive virus replication. BAC,
bacterial artificial chromosome. (B) Dose-dependent regulation of ADddUL79 replication by Shield-1. Human foreskin fibroblasts (HFFs) were
infected with ADddUL79 at a multiplicity of infection (MOI) of 3 in the presence of various concentrations of Shield-1 (as indicated). At 96 h
postinfection (hpi), supernatants of infected cells were collected and analyzed for the presence of virus by TCID50 assay in HFFs maintained in
1 !M Shield-1. (C) HFFs overexpressing the hemagglutinin (HA)-tagged UL79 complemented the growth of ADddUL79 in the absence of
Shield-1. Normal HFFs (HF) o HFFs overexpressing the HA-tagged UL79 (HF-UL79HA) wer infected with the ADwt (wild-type virus control)
or ADddUL79 virus at an MOI of 3 with Shield-1 or without Shield-1. At 120 hpi, the titers of cell-free virus were determined as described above
for panel B (left panel), and total cell lysates were analyzed for the expression of the tagged UL79 by immunoblotting using the anti-HA antibody
("-HA) (right panel). The antibody to actin was used as a loading control. The detection limit of the TCID50 assay is indicated by the dashed line.
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presence of virus by TCID50 assay in HFFs maintained in 1 µM Shield-1.  (C) HFFs 
overexpressing the hemagglutinin (HA)-tagged UL79 complemented the growth of 
ADddUL79 in the absence of Shield-1.  Normal HFFs (HF) or HFFs overexpressing the HA-
tagged UL79 (HF-UL79HA) were infected with the ADwt (wild-type virus control) or 
ADddUL79 virus at an MOI of 3 with Shield-1 or without Shield-1.  At 120 hpi, the titers of 
cell-free virus were determined as described above for panel B (left panel), and total cell 
lysates were analyzed for the expression of the tagged UL79 by immunoblotting using the 
anti-HA antibody (α-HA) (right panel).  The antibody to actin was used as a loading control.  
The detection limit of the TCID50 assay is indicated by the dashed line. 
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Figure 2.2.  UL79 is essential for HCMV replication at late stages of infection. (A) 
Growth kinetic analysis of ADddUL79 in the presence or absence of Shield-1.  HFFs were 
infected with ADwt or ADddUL79 at an MOI of 3 for single-step growth analysis or at an 
MOI of 0.1 for multistep growth analysis.  Infected cells were cultivated in the presence (+) 
or absence (-) of 1 µM Shield-1, and supernatants were collected at the indicated times and 
analyzed for the presence of virus by TCID50 assay in HFFs maintained in 1 µM Shield-1 (-/+ 
or -/+).  To test the potential occurrence of spontaneous escape mutants after prolonged 
growth of recombinant virus, supernatants from cells infected with ADddUL79 in the 
absence of Shield-1 were also analyzed by TCID50 assay in the absence of Shield-1 (-/-).  (B) 
UL79 is required at late stages of HCMV infection.  HFFs were infected with ADddUL79 at 
an MOI of 0.1, Shield-1 (Shld1) was added at the indicated times postinfection, and infected 
cells were cultivated with Shield-1 for various time periods (indicated by the white boxes in 
defect of ADddUL79 in the absence of Shield-1 is the direct
result of the abrogation of UL79.
UL79 is essential for HCMV replication. To characterize the
role of UL79 in HCMV replication, we first analyzed the
growth kinetics of the ADddUL79 virus in HFFs. For progeny
virus collected at each time point, we determined the titer of
virus in the presence and absence of Shield-1 to determine
whether there were additional escape mutations acquired dur-
ing the course of infection. Under the multistep growth con-
dition, ADddUL79 replicated indistinguishably from ADwt in
the presence of Shield-1. However, without Shield-1, the pro-
duction of ADddUL79 was almost undetectable by 12 days
postinfection (dpi), whereas ADwt growth peaked and the
titers reached 1 ! 107 TCID50 units/ml (Fig. 2A). It was noted
that at 15 dpi in the absence of Shield-1, ADddUL79 started to
produce very low levels of progeny that could be determined
even in the absence of Shield-1. We interpreted these results
to mean that ADddUL79 might acquire spontaneous escape
mutations after a prolonged period under nonpermissive con-
ditions.
Next, we examined the single-step growth kinetics of
ADddUL79 to determine whether the defect was dependent
on the MOI. At an MOI of 3 and in the absence of Shield-1,
ADddUL79 produced almost no virus by 4 dpi and very low
levels of progeny ("1 ! 103 TCID50 units/ml) by 6 dpi, while
ADwt reached peak titers of 1 ! 107 TCID50 units/ml (Fig.
2A). In contrast, Shield-1 treatment restored the growth of
ADddUL79 to wild-type levels. The very low levels of
ADddUL79 produced after 5 dpi in the absence of Shield-1
might be due to the slight leakiness of Shield-1 regulation of
ddFKBP degradation (3). It was unlikely that this low level of
virus growth represented escape mutants because they could
not establish a second round of infection without Shield-1,
their titers did not increase over time, and their titers could not
be measured without Shield-1.
Taken together, these data indicate that UL79 is essential
for HCMV replication in cultured fibroblasts and that
ddFKBP-mediated Shield-1 regulation allows for tight con-
trol of UL79 function during the virus infection cycle.
UL79 is required for viral replication at late stages of in-
fection. To determine when UL79 is required during the viral
replication cycle, we stabilized UL79 protein accumulation by
Shield-1 at various time points and for different lengths of time
in infected cells and then determined the impact of such tem-
poral accumulation of UL79 proteins on virus production. To
determine whether UL79 was required at early times, Shield-1
was added at the onset of virus infection but was removed from
the medium at 24 or 48 hpi. To determine whether UL79 was
required at late times during infection, Shield-1 was added at
24 or 48 hpi. In both experiments, the titers of virus in the
supernatants of infected cells were determined at 120 hpi (Fig.
2B). When we added Shield-1 as late as 48 hpi, ADddUL79
replication was indistinguishable from virus grown in the con-
tinuous presence of Shield-1. In contrast, when Shield-1 was
present for only the first 48 h during infection, almost no viral
progeny were produced, similar to ADddUL79 infection in the
complete absence of Shield-1. Taken together, these data in-
dicate that UL79 is required for viral replication during the
late stages of viral infection.
UL79 is required for late viral gene expression. To deter-
mine which step of the viral replication cycle was compromised
in the absence of UL79, we first examined the viral protein
accumulation profile in the absence of Shield-1. The accumu-
lation of viral immediate-early proteins (IE1-72 and IE2-86) or
early/early-late proteins (UL38, UL44, UL69, and pp65) in
cells infected with ADddUL79 was not affected (Fig. 3 and
data not shown). In contrast, the true late proteins, pp28, pp71,
and pp150, accumulated at markedly reduced levels.
To determine whether the reduced late protein accumula-
tion in ADddUL79 infection was the result of reduced viral
late transcript accumulation, we analyzed the IE1 transcript
(control) and late UL32 (pp150), UL82 (pp71), and cotermi-
nated UL93-99 transcripts by RT-qPCR analysis (Fig. 4) (16,
38, 57). All transcripts detected were specific and were not the
result of genomic DNA contamination, as mock-infected cells
and qPCR reactions done in the absence of reverse transcrip-
tase failed to produce any products (data not shown). At 24
hpi, late transcripts were barely detectable, whereas the IE1
transcript accumulated to a high level (data not shown). Im-
portantly, stabilization of UL79 by Shield-1 had no substantial
FIG. 2. UL79 is essential for HCMV replication at late stages of
infection. (A) Growth kinetic analysis of ADddUL79 in the presence
or absence of Shield-1. HFFs were infected with ADwt or ADddUL79
at an MOI of 3 for single-step growth analysis or at an MOI of 0.1 for
multistep growth analysis. Infected cells were cultivated in the pres-
ence (#) or absence ($) of 1 %M Shield-1, and supernatants were
collected at the indicated times and analyzed for the presence of virus
by TCID50 assay in HFFs maintained in 1 %M Shield-1 (#/# or $/#).
To test the potential occurrence of pontaneous escape mutan s after
prolonged growth of recombinant virus, supernatants from cells in-
fected with ADddUL79 in the absence of Shield-1 were also analyzed
by TCID50 assay in the absence of Shield-1 ($/$). (B) UL79 is re-
quired at late stages of HCMV infection. HFFs were infected with
ADddUL79 at an MOI of 0.1, Shield-1 (Shld1) was added at the
indicated times postinfection, and infected cells were cultivated with
Shield-1 for various time periods (indicated by the white boxes in the
schematic drawing in the left panel). Supernatants were collected at
120 hp and analyzed for the presence of virus by the TCID50 assay in
HFFs maintained in 1 %M Shield-1 (right panel). The number of hours
of Shield-1 treatment are shown in parentheses t th right of the
graph. The detection limits of the TCID50 assay are indicated by
dashed lines in the graphs.
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the schematic drawing in the left panel).  Supernatants were collected at 120 hpi and analyzed 
for the presence of virus by the TCID50 assay in HFFs maintained in 1 µM Shield-1 (right 
panel).  The number of hours of Shield-1 treatment are shown in parentheses to the right of 
the graph.  The detection limits of the TCID50 assay are indicated by dashed lines in the 
graphs. 
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Figure 2.3.  UL79 is required for the efficient accumulation of late viral proteins during 
HCMV infection.  HFFs were infected with ADddUL79 at an MOI of 3 in the presence (+) 
or absence (-) of 1 µM Shield-1.  Cells were harvested at different times post-infection.  The 
accumulation of immediate-early proteins (IE1-72 and IE2-86), early proteins (pUL38 and 
pUL44), and late proteins (pp71, pp150, and pp28) were determined by immunoblot analysis. 
effects on viral transcript accumulation at this time point (Fig.
4), consistent with the observation that UL79 was not required
at early times of infection (Fig. 2B). At 72 hpi, even though
degradation of UL79 had only a small effect on IE1 transcript
accumulation, as the viral DNA synthesis inhibitor phospho-
noacetic acid (PAA) did (16), it reduced the accumulation of
late transcripts almost as markedly as PAA did. The levels of
late UL32, UL82, and UL93-99 transcripts when UL79 was
absent were 7-, 27-, and 13-fold lower than the levels when
UL79 was present, respectively (Fig. 4).
Together, our results indicate that UL79 has minimal effect
on viral immediate-early and early gene expression but is crit-
ical for the accumulation of late viral transcripts and proteins.
UL79 is dispensable for viral DNA replication. As viral late
gene expression is dependent on viral DNA replication, it was
possible that the defect in late gene expression in the absence
of UL79 was due to a defect in viral DNA replication. Thus, we
examined viral DNA synthesis in the absence of Shield-1 (Fig.
5A). Surprisingly, the kinetics of viral DNA replication during
ADddUL79 infection in cells in the absence of Shield-1 was
indistinguishable from that of infection of cells in the presence
of Shield-1. To confirm that Shield-1 withdrawal was effective,
supernatants from infected culture were collected at 72 hpi and
measured for virus production (Fig. 5B). Infected cells in the
absence of Shield-1 produced no detectable virus, indicating
that UL79 function was indeed abrogated in these cells. There-
fore, we conclude that UL79 acts after viral DNA replication
and is specifically required for the accumulation of late viral
transcripts.
The UL79 transcript is expressed with early-late kinetics
and is regulated by a positive-feedback loop. To determine the
kinetic class of UL79 expression, we analyzed the UL79 tran-
script accumulation in fibroblasts infected with ADddUL79 by
RT-qPCR (Fig. 6A). When the UL79 protein was stabilized,
the UL79 transcript accumulated abundantly at late times of
infection, and its level at 72 hpi was 5-fold higher than the level
at 24 hpi. The UL79 transcript level was markedly reduced at
72 hpi when infected cells were treated with PAA, indicating
that its transcript accumulation was augmented by viral DNA
replication. However, in the presence of PAA, the accumula-
tion of UL79 transcript was not completely inhibited, as the
UL79 transcript levels increased almost 3-fold from 24 to 72
FIG. 3. UL79 is required for the efficient accumulation of late viral
proteins during HCMV infection. HFFs were infected with
ADddUL79 at an MOI of 3 in the presence (!) or absence (") of 1
#M Shield-1. Cells were harvested at different times postinfection. The
accumulation of immediate-early proteins (IE1-72 and IE2-86), early
proteins (pUL38 and pUL44), and late proteins (pp71, pp150, and
pp28) were determined by immunoblot analysis.
FIG. 4. UL79 is required for the efficient accumulation of late viral
transcripts during HCMV infection. HFFs were infected with
ADddUL79 at an MOI of 3 in the presence (!) or absence (") of
Shield-1 (Shld1) (1 #M) and with or without the viral DNA synthesis
inhibitor phosphonoacetic acid (PAA) (100 #g/ml). Total RNA was
isolated at 24 and 72 hpi, and the amounts of selected viral transcripts
were then measured by reverse transcription coupled to quantitative
PCR (RT-qPCR) and normalized to that of GAPDH. The normalized
amount of viral transcript at 24 hpi in the presence of Shield-1 but
without PAA was set at 1.
FIG. 5. Viral DNA replication is not altered in the absence of
UL79 during infection. HFFs were infected with ADddUL79 in the
presence or absence of 1 #M Shield-1. (A) Total DNA was isolated at
different times postinfection, and the accumulation of viral DNA was
determined by qPCR using primers specific for the HCMVUL54 gene.
(B) Supernatants of infected cells with or without Shield-1 treatment
were also collected at 72 hpi and analyzed for the presence of virus by
the TCID50 assay in HFFs maintained in 1 #M Shield-1. The detection
limit of the TCID50 assay is indicated by the dashed line.
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Figure 2.4.  UL79 is required for the efficient accumulation of late viral transcripts 
during HCMV infection.  HFFs were infected with ADddUL79 at an MOI of 3 in the 
presence (+) or absence (-) of Shield-1 (Shld1) (1 µM) and with or without the viral DNA 
synthesis inhibitor phosphonoacetic acid (PAA) (100 µg/ml).  Total RNA was isolated at 24 
and 72 hpi, and the amounts of selected viral transcripts were then measured by reverse 
transcription coupled to quantitative PCR (RT-qPCR) and normalized to that of GAPDH.  
The normalized amount of viral transcript at 24 hpi in the presence of Shield-1 but without 
PAA was set at 1. 
 
 
effects on viral transcript accumulation at this time point (Fig.
4), consistent with the observation that UL79 was not required
at early times of infection (Fig. 2B). At 72 hpi, even though
degradation of UL79 had only a small effect on IE1 transcript
accumulation, as the viral DNA synthesis inhibitor phospho-
noacetic acid (PAA) did (16), it reduced the accumulation of
late transcripts almost as markedly as PAA did. The levels of
late UL32, UL82, and UL93-99 transcripts when UL79 was
absent were 7-, 27-, and 13-fold lower than the levels when
UL79 was present, respectively (Fig. 4).
Together, our results indicate that UL79 has minimal effect
on viral immediate-early and early gene expression but is crit-
ical for the accumulation of late viral transcripts and proteins.
UL79 is dispensable for viral DNA replication. As viral late
gene expression is dependent on viral DNA replication, it was
possible that the defect in late gene expression in the absence
of UL79 was due to a defect in viral DNA replication. Thus, we
examined viral DNA synthesis in the absence of Shield-1 (Fig.
5A). Surprisingly, the kinetics of viral DNA replication during
ADddUL79 infection in cells in the absence of Shield-1 was
indistinguishable from that of infection of cells in the presence
of Shield-1. To confirm that Shield-1 withdrawal was effective,
supernatants from infected culture were collected at 72 hpi and
measured for virus production (Fig. 5B). Infected cells in the
absence of Shield-1 produced no detectable virus, indicating
that UL79 function was indeed abrogated in these cells. There-
fore, we conclude that UL79 acts after viral DNA replication
and is specifically required for the accumulation of late viral
transcripts.
The UL79 transcript is expressed with early-late kinetics
and is regulated by a positive-feedback loop. To determine the
kinetic class of UL79 expression, we analyzed the UL79 tran-
script accumulation in fibroblasts infected with ADddUL79 by
RT-qPCR (Fig. 6A). When the UL79 protein was stabilized,
the UL79 transcript accumulated abundantly at late times of
infection, and its level at 72 hpi was 5-fold higher than the level
at 24 hpi. The UL79 transcript level was markedly reduced at
72 hpi when infected cells were treated with PAA, indicating
that its transcript accumulation was augmented by viral DNA
replication. However, in the presence of PAA, the accumula-
tion of UL79 transcript was not completely inhibited, as the
UL79 transcript levels increased almost 3-fold from 24 to 72
FIG. 3. UL79 is required for the efficient accumulation of late viral
proteins during HCMV infection. HFFs were infected with
ADddUL79 at an MOI of 3 in the presence (!) or absence (") of 1
#M Shield-1. Cells were harvested at different times postinfection. The
accumulation of immediate-early proteins (IE1-72 and IE2-86), early
proteins (pUL38 and pUL44), and late proteins (pp71, pp150, and
pp28) were determined by immunoblot analysis.
FIG. 4. UL79 is required for the efficient accumulation of late viral
transcripts during HCMV infection. HFFs were infected with
ADddUL79 at an MOI of 3 in the presence (!) or absence (") of
Shield-1 (Shld1) (1 #M) and with or without the viral DNA synthesis
inhibitor phosphonoacetic acid (PAA) (100 #g/ml). Total RNA was
isolated at 24 and 72 hpi, and the amounts of selected viral transcripts
were the measured by revers transcription coupled to quantita ive
PCR (RT-qPCR) and normalized to that of GAPDH. The normalized
amount of viral transcript at 24 hpi in the presence of Shi ld-1 but
without PAA was set at 1.
FIG. 5. Viral DNA replication is not altered in the absence of
UL79 during infection. HFFs were infected with ADddUL79 in the
presence or absence of 1 #M Shield-1. (A) Total DNA was isolated at
different times postinfection, and the accumulation of viral DNA was
determined by qPCR using primers specific for the HCMVUL54 gene.
(B) Supernatants of infected cells with or without Shield-1 treatment
were also collected at 72 hpi and analyzed for the presence of virus by
the TCID50 assay in HFFs maintained in 1 #M Shield-1. The detection
limit of the TCID50 assay is indicated by the dashed line.
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Figure 2.5.  Viral DNA replication is not altered in the absence of UL79 during 
infection.  HFFs were infected with ADddUL79 in the presence or absence of 1 µM Shield-1.  
(A) Total DNA was isolated at different times postinfection, and the accumulation of viral 
DNA was determined by qPCR using primers specific for the HCMV UL54 gene.  (B) 
Supernatants of infected cells with or without Shield-1 treatment were also collected at 72 hpi 
and analyzed for the presence of virus by the TCID50 assay in HFFs maintained in 1 µM 
Shield-1.  The detection limit of the TCID50 assay is indicated by the dashed line. 
 
 
 effects on viral transcript accumulation at this time point (Fig.
4), consistent with the observation that UL79 was not required
at early times of infection (Fig. 2B). At 72 hpi, even though
degradation of UL79 had only a small effect on IE1 transcript
accumulation, as the viral DNA synthesis inhibitor phospho-
noac tic acid (PAA) did (16), it reduced the accumulation of
late transcripts almost as markedly as PAA did. The levels of
late UL32, UL82, and UL93-99 transcripts when UL79 was
absent were 7-, 27-, and 13-fold lower than the levels when
UL79 was present, respectively (Fig. 4).
Together, our results indicate that UL79 has minimal effect
on viral immediate-early and early gene expression but is crit-
ical for the accumulation of late viral transcripts and proteins.
UL79 is dispensable for viral DNA replication. As viral late
gene expression is dependent on viral DNA replication, it was
possible that the defect in late gene expression in the absence
of UL79 was due to a defect in viral DNA replication. Thus, we
examined viral DNA synthesis in the absence of Shield-1 (Fig.
5A). Surprisingly, the kinetics of viral DNA replication during
ADddUL79 infection in cells in the absence of Shield-1 was
indistinguishable from that of infection of cells in the presence
of Shield-1. To confirm that Shield-1 withdrawal was effective,
supernatants from infected culture were collected at 72 hpi and
measured for virus production (Fig. 5B). Infected cells in the
absence of Shield-1 produced no detectable virus, indicating
that UL79 function was indeed abrogated in these cells. There-
fore, we conclude that UL79 acts after viral DNA replication
and is specifically required for the accumulation of late viral
transcripts.
The UL79 transcript is expressed with early-late kinetics
and is regulated by a positive-feedback loop. To determine the
kinetic class of UL79 expression, we analyzed the UL79 tran-
script accumulation in fibroblasts infected with ADddUL79 by
RT-qPCR (Fig. 6A). When the UL79 protein was stabilized,
the UL79 transcript accumulated abundantly at late times of
infection, and its level at 72 hpi was 5-fold higher than the level
at 24 hpi. The UL79 transcript level was markedly reduced at
72 hpi when infected cells were treated with PAA, indicating
that its transcript accumulation was augmented by viral DNA
replication. However, in the presence of PAA, the accumula-
tion of UL79 transcript was not completely inhibited, as the
UL79 transcript levels increased almost 3-fold from 24 to 72
FIG. 3. UL79 is required for the efficient accumulation of late viral
proteins during HCMV infection. HFFs were infected with
ADddUL79 at an MOI of 3 in the presence (!) or absence (") of 1
#M Shield-1. Cells were harvested at different times postinfection. The
accumulation of immediate-early proteins (IE1-72 and IE2-86), early
proteins (pUL38 and pUL44), and late proteins (pp71, pp150, and
pp28) were determined by immunoblot analysis.
FIG. 4. UL79 is required for the efficient accumulation of late viral
transcripts during HCMV infection. HFFs were infected with
ADddUL79 at an MOI of 3 in the presence (!) or absence (") of
Shield-1 (Shld1) (1 #M) and with or without the viral DNA synthesis
inhibitor phosphonoacetic acid (PAA) (100 #g/ml). Total RNA was
isolated at 24 and 72 hpi, and the amounts of selected viral transcripts
were then measured by reverse transcription coupled to quantitative
PCR (RT-qPCR) and normalized to that of GAPDH. The normalized
amount of viral transcript at 24 hpi in the presence of Shield-1 but
without PAA was set at 1.
FIG. 5. Viral DNA replication is not altered in the absence of
UL79 during infection. HFFs were infected with ADddUL79 in the
presence or absence of 1 #M Shield-1. (A) Total DNA was isolated at
different times postinfection, and the accumulation of viral DNA was
d termined by qPCR us ng primers specific for the HCMVUL54 ene.
(B) Supernatants of infected cells with or without Shield-1 treatment
were also coll cted at 72 pi and analyzed for the p esenc f virus by
the TCID50 assay in HFFs maintained in 1 #M Shield-1. The detection
limit of the TCID50 assay is indicated by the dashed line.
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Figure 2.6.  UL79 is transcribed with early-late kinetics and is regulated by a positive-
feedback loop.  (A) HFFs were infected with ADddUL79 at an MOI of 3 in the presence or 
absence of Shield-1 (1 µM) and with or without the viral DNA synthesis inhibitor PAA (100 
µg/ml).  Total RNA was isolated at 24 and 72 hpi, and the amount of UL79 transcript was 
measured by RT-qPCR analysis and normalized to that of GAPDH.  The normalized amount 
of UL79 transcript at 24 hpi in the presence of Shield-1 but without PAA was set at 1.  (B) 
HFFs expressing the HA-tagged UL79 (HF-UL79HA) or empty vector (HF-vector) were 
infected with ADddUL79 at an MOI of 3 in the absence of Shield-1 and with or without PAA 
(100 µg/ml).  Total RNA was isolated at 24 and 72 hpi, and the amount of ddFKBP-tagged 
UL79 transcript expressed from the viral genome was measured by RT-qPCR analysis using 
the primers specific to the ddFKBP sequence and normalized to that of GAPDH.  The 
normalized amount of ddFKBP-tagged UL79 transcript at 24 hpi without PAA in infected 
HF-UL79HA cells was set at 1. 
hpi. Therefore, as the accumulation of UL79 transcript is
markedly enhanced by, but not com letely dependent on viral
DNA synthesis, our data suggest that UL79 is an early-late
HCMV gene. However, in the present study, we cannot rule
out the possibility that more than one transcript emanates
from the UL79 locus and that our result reflects the combined
expression profile of these transcripts rather than individual
species.
Surprisingly, when UL79 proteins were destabilized, the
level of UL79 transcript was drastically reduced in infected
cells at 72 hpi (Fig. 6A). This suggests an a positive-feedback
loop for UL79 expression which in turn amplifies the expres-
sion of late viral genes. To provide additional evidence for this
autoregulation of UL79 transcription by its protein products,
we tested whether we could enhance endogenous UL79 tran-
scription during infection of UL79 recombinant virus by pro-
viding the UL79 protein in trans. We infected HFFs expressing
the HA-tagged UL79 (HF-UL79HA cells) or empty vector
(HF-vector cells) with ADddUL79 in the absence of Shield-1.
This experimental system allowed us to uncouple the UL79
protein accumulation (provided by HF-UL79HA cells) and
endogenous UL79 transcript accumulation (from the viral ge-
nome). The endogenous UL79 transcription was analyzed by
RT-qPCR using a primer pair specific to the ddFKBP se-
quence. We found that the accumulation of ddFKBP-UL79
transcripts in infected HF-UL79HA cells markedly increased
at 72 hpi relative to that in infected HF-vector cells. This
indicates that, as anticipated, the UL79 protein enhances the
transcription from the UL79 gene locus (Fig. 6B).
Together, these results suggest that efficient transcription of
UL79 is positively regulated by both viral DNA replication and
its own protein products.
A UL79 stop codon mutant virus has the same defect as
ADddUL79. To provide additional proof that the defect of
ADddUL79 was the direct result of the loss of UL79 function,
we created a second UL79 mutant virus, ADinUL79stop. In this
recombinant virus, we inserted a stop codon at residue Glu6 of
the UL79 ORF to abrogate the expression of UL79 protein
products (Fig. 7A). The ADinUL79stop virus could be recon-
stituted only from transfection of the BAC clone in HF-
UL79HA cells, not by transfection in normal HFFs or HF-
vector cells. The titer of reconstituted mutant virus was
comparable to that of wild-type virus (data not shown), and it
replicated efficiently in HF-UL79HA cells but completely
failed to grow in HF-vector cells (Fig. 7B). These results indi-
cated that loss of UL79 function was solely responsible for the
growth defect of ADinUL79stop. Importantly, cells infected
with ADinUL79stop synthesized viral DNA at wild-type levels
(Fig. 7C) and accumulated the products of IE genes (IE1-72
and IE2-86) and early genes (pUL38 and pUL44) efficiently
but had a marked defect in accumulation of viral late proteins
(pp71 and pp28) during infection (Fig. 7D). Therefore, the
defect of ADinUL79stop phenocopied that of ADddUL79 un-
der Shield-1 withdrawal, and our results provide further vali-
dation for the power of the protein stability-based conditional
approach to dissect the role of viral factors in HCMV biology.
The HA-tagged UL79 protein is primarily nuclear and lo-
calizes in replication compartments during virus infection. As
UL79 is required for the accumulation of late viral transcripts,
it is possible that it is a nuclear protein involved in the regu-
lation of viral late gene transcription. We first examined the
intracellular distribution of UL79 expressed alone to deter-
mine its ability to localize into the nucleus in the absence of
any other viral factors. We used HF-UL79HA cells because
there was no antibody specific to UL79 available and because
the tagged UL79 was fully functional to complement UL79-
deficient virus (Fig. 1C). While no appreciable HA staining was
present in normal HFFs, the staining was readily observed in
HF-UL79HA cells, predominantly localizing within the nuclei,
suggesting that UL79 proteins are primarily nuclear (Fig. 8A).
Next we determined whether the UL79 proteins localized to
any virus-induced intracellular structures during infection, par-
ticularly replication compartments. These organized intranu-
clear viral structures are sites where sets of viral proteins (e.g.,
pUL44, pUL57, pUL117, and IE2) (1, 44, 46) and cellular
proteins (e.g., p53, Nbs1, and Rad50) (18, 32) are recruited to,
and viral activities, including viral DNA synthesis, late gene
transcription, and DNA packaging, take place. To test our
hypothesis, we examined the localization of the HA-tagged
UL79 proteins expressed from HF-UL79HA cells that were
infected with HCMV, as we were not able to detect tagged
UL79 proteins expressed from the endogenous locus of the
viral genome during infection (data not shown). The tagged
UL79 proteins formed large intranuclear domains which colo-
calized with pUL44, the virus-encoded DNA polymerase ac-
cessory protein that has been used as a marker for replication
compartments (44, 46) (Fig. 8A), indicating that a major frac-
tion of HA-tagged UL79 proteins is localized in replication
compartments. Importantly, the formation of UL79-containing
large intracellular domains appeared to occur at late times
FIG. 6. UL79 is transcribed with early-late kinetics and is regulated
by a positive-feedback loop. (A) HFFs were infected with ADddUL79
at an MOI of 3 in the presence or absence of Shield-1 (1 !M) and with
or without the viral DNA synthesis inhibitor PAA (100 !g/ml). Total
RNA was isolated at 24 and 72 hpi, and the amount of UL79 transcript
was measured by RT-qPCR analysis nd normalized to that of
GAPDH. The normalized amount of UL79 transcript at 24 hpi in the
presence of Shield-1 but without PAA was set at 1. (B) HFFs express-
ing the HA-tagged UL79 (HF-UL79HA) or empty vector (HF-vector)
were infected with ADddUL79 at an MOI of 3 in the absence of
Shield-1 and with or without PAA (100 !g/ml). Total RNA was iso-
lated at 24 and 72 hpi, and the amount of ddFKBP-tagged UL79
transcript expressed from the viral gen me was measured by RT-
qPCR analysis using the primers specific to the ddFKBP sequence and
normalized to that of GAPDH. The normalized amount of ddFKBP-
tagged UL79 transcript at 24 hpi without PAA in infected HF-
UL79HA cells was set at 1.
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Figure 2.7.  A mutant virus in which the UL79 ORF has been abrogated by a stop codon 
mutation has the same defect as ADddUL79.  (A) Schematic diagram for creating 
recombinant virus ADinUL79stop.  A cassette that contained a stop codon followed by the 
FRT-bracketed GalK/kanamycin dual marker was amplified and recombined into the UL79 
ORF of the wild-type HCMV BAC clone.  The GalK/kanamycin marker was then removed 
by Flp/FRT recombination.  The final clone, ADinUL79stop, contained a stop codon along 
with a small FRT site inserted in frame at the 6th amino acid (E6X) of the UL79 ORF.  (B) 
Single-step growth analysis of ADinUL79stop.  Complementing HF-UL79HA cells or control 
HF-vector cells were infected with ADwt or ADinUL79stop at an MOI of 3.  Supernatants 
were collected at the indicated days postinfection and analyzed for the presence of virus by 
TCID50 assay in HF-UL79HA cells.  The detection limit of the TCID50 assay is indicated by 
during infection (Fig. 8B), providing additional evidence that
UL79 functions at late times to regulate gene expression.
We noted that the anti-HA antibody also appeared to gen-
erate low-level cytoplasmic staining in some normal HFFs that
were infected with HCMV, even though this staining intensi-
fied in infected cells that expressed the tagged UL79 protein
(Fig. 8A). This cytoplasmic staining colocalized with pp28-
containing viral assembly cent rs (data not shown). Nonethe-
less, we decided not to pursue this further, as we could not rule
out the possibility that the cytoplasmic HA staining represents
the nonspecific recognition of assembly centers by anti-HA
antibody.
The UL79 protein is not detected in HCMV virions. A pro-
teomics study has previously shown that a single UL79-derived
peptide can be detected in the HCMV virions only by the
sensitive Fourier transform ion cyclotron resonance (FTICR)
mass spectrometry, not by the more traditional liquid chroma-
tography-tandem mass spectrometry (LC-MS-MS) analysis,
suggesting that this peptide may represent a nonspecific con-
taminant (55). To determine whether the UL79 protein is a
tegument protein, we infected HF-UL79HA cells or HF-
vector cells with ADddUL79 in the presence or absence of
Shield-1. We then harvested supernatants from infected
cells at 96 hpi and partially purified cell-free virions by
ultracentrifugation through a sorbitol cushion. These virion
samples appeared to be largely free of contamination of
cellular debris, as they did not contain detectable amounts
of the viral IE1 protein or the cellular PCNA protein (Fig.
9). On the other hand, the major capsid protein (MCP) was
readily detected, and importantly, pUL69, a protein that is
present in the tegument and dense bodies in very small
amounts (55, 59), could also be detected in the virion sam-
ples (Fig. 9). Under these conditions, however, we could not
detect the HA-tagged UL79 protein in the virion samples,
FIG. 7. A mutant virus in which the UL79 ORF has been abrogated by a stop codon mutation has the same defect as ADddUL79.
(A) Schematic diagram for creating recombinant virus ADinUL79stop. A cassette that contained a stop codon followed by the FRT-bracketed
GalK/kanamycin dual marker was amplified and recombined into the UL79 ORF of the wild-type HCMV BAC clone. The GalK/kanamycin
marker was then removed by Flp/FRT recombination. The final clone, ADinUL79stop, contained a stop codon along with a small FRT site inserted
in frame at the 6th amino acid (E6X) of the UL79 ORF. (B) Single-step growth analysis of ADinUL79stop. Complementing HF-UL79HA cells or
control HF-vector cells were infected with ADwt or ADinUL79stop at an MOI of 3. Supernatants were collected at the indicated days postinfection
and analyzed for the presence of virus by TCID50 assay in HF-UL79HA cells. The detection limit of the TCID50 assay is indicated by the dashed
line. (C) Viral DNA replication of inUL79stop. HF-UL79HA cells or HF-vector cells were infected with ADinUL79stop at an MOI of 3. Total
DNA was isolated at different times postinfection, and the accumulation of viral DNA was determined by qPCR using primers specific for the
HCMVUL54 gene. (D) Viral gene expression of ADinUL79stop. HF-UL79HA cells or HF-vector cells were infected with ADinUL79stop at an MOI
of 3. Cells were ha vested at different times postinfection. The accumulation of immediate-early proteins (IE1-72 and IE2-86), early proteins
(pUL38 and pUL44), and late proteins (pp71 and pp28) was determined by immunoblot analysis.
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the dashed line.  (C) Viral DNA replication of ADinUL79stop.  HF-UL79HA cells or HF-
vector cells were infected with ADinUL79stop at an MOI of 3.  Total DNA was isolated at 
different times postinfection, and the accumulation of viral DNA was determined by qPCR 
using primers specific for the HCMV UL54 gene.  (D) Viral gene expression of 
ADinUL79stop. HF-UL79HA cells or HF-vector cells were infected with ADinUL79stop at an 
MOI of 3. Cells were harvested at different times postinfection.  The accumulation of 
immediate-early proteins (IE1-72 and IE2-86), early proteins (pUL38 and pUL44), and late 
proteins (pp71 and pp28) was determined by immunoblot analysis. 
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Figure 2.8.  UL79 proteins are primarily nuclear proteins that localize within viral 
replication compartments during infection.  (A) Normal HFFs or HF-UL79HA cells were 
FIG. 8. UL79 proteins are primarily nuclear proteins that localize within viral replication compartments during infection. (A) Normal HFFs or
HF-UL79HA cells were either mock infected or infected with the GFP-less wild-type HCMV virus ADwt.2 at an MOI of 0.5. At 72 hpi, the cells
were harvested and examined by confocal immunofluorescence analysis for the localization of UL79 using anti-HA antibody and viral replication
compartments using anti-pUL44 antibody. The cells were also counterstained with TO-PRO3 to visualize the nuclei. Mock-infected HFFs or HFFs
infected with ADwt.2 were used as a negativ control for the detectio of tagged UL79 proteins by anti-HA antibody. (B) HF-UL79HA cells were
either mock infected or infected with ADwt.2 at an MOI of 0.5. At different times postinfection, cells were examined by confocal fluorescence
analysis for viral replication compartments using anti-pUL44 antibody and UL79 localization using anti-HA antibody. The cells were also
counterstained with TO-PRO3 to visualize the nuclei. The white arrows indicate viral replication compartments, and the yellow arrows indicate
the localization of a portion of HA staining to viral assembly center-like cytoplasmic structures. Bars, 20 !m.
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either mock infected or infected with the GFP-less wild-type HCMV virus ADwt.2 at an MOI 
of 0.5.  At 72 hpi, the cells were harvested and examined by confocal immunofluorescence 
analysis for the localization of UL79 using anti-HA antibody and viral replication 
compartments using anti-pUL44 antibody.  The cells were also counterstained with TO-
PRO3 to visualize the nuclei.  Mock-infected HFFs or HFFs infected with ADwt.2 were used 
as a negative control for the detection of tagged UL79 proteins by anti-HA antibody.  (B) HF-
UL79HA cells were either mock infected or infected with ADwt.2 at an MOI of 0.5.  At 
different times postinfection, cells were examined by confocal fluorescence analysis for viral 
replication compartments using anti-pUL44 antibody and UL79 localization using anti-HA 
antibody.  The cells were also counterstained with TO-PRO3 to visualize the nuclei.  The 
white arrows indicate viral replication compartments, and the yellow arrows indicate the 
localization of a portion of HA staining to viral assembly center-like cytoplasmic structures.  
Bars, 20 µm. 
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Figure 2.9.  The UL79 protein is not detected in HCMV virions.  A total of 1X107 HF-
UL79HA or HF-vector cells were infected with ADddUL79 in the presence or absence of 
Shield-1 at an MOI of 5.  Total cell lysates and cell-free virions were collected at 96 hpi.  
Cell- free virions were then partially purified by ultracentrifugation through a sorbitol 
cushion.  Lysates of 1X105 cells or 20% of total virion samples harvested were loaded onto 
each lane of an SDS-polyacrylamide gel and analyzed by immunoblotting for MCP, IE1-72, 
pUL69, and cellular PCNA.  For the UL79 protein, twice as many virion samples were used 
in the experiment, and the protein was analyzed using anti-HA antibody. 
even though it was readily detectable in total lysate of in-
fected HF-UL79HA cells. Thus, the UL79 protein is un-
likely to be a major component of the HCMV virion. This
was consistent with the result that UL79 appeared to be
required only at late stages (i.e., after 48 hpi) (Fig. 2B) and
suggested the important role of the newly synthesized UL79
protein in promoting the HCMV lytic infection cycle.
Collectively, our data indicate that UL79 plays a key role at
late times after viral DNA replication to regulate the accumu-
lation of late viral transcripts.
DISCUSSION
In this study, we applied the ddFKBP-mediated, Shield-1-
regulated protein genetic approach (3) to investigate the role
of viral gene UL79 during HCMV replication. Moreover, we
also compared the effectiveness of this approach to the more
traditional viral genetic approach by creating and analyzing the
second UL79 mutant virus in which the UL79 ORF was dis-
rupted by a stop codon mutation (Fig. 7). This comparative
analysis provides additional proof for the power of the protein
stability-based conditional approach to dissect the role of viral
factors in HCMV biology. Our work represents one of the few
studies that take advantage of this powerful approach to define
viral gene functions in HCMV biology (20, 45). Shield-1 reg-
ulation of ddFKBP-tagged UL79 is robust, reversible, and pre-
cisely controlled and validates the role of UL79 as an essential
HCMV gene (Fig. 1 and 2). Interestingly, we could not detect
ddFKBP-tagged UL79 protein in cells infected with
ADddUL79 even with Shield-1 using an anti-FKBP12 anti-
body. Nonetheless, the full complementation of ADddUL79 in
the absence of Shield-1 by HFFs overexpressing UL79 pro-
vided additional evidence that the defect of ADddUL79 was
the direct result of UL79 depletion (Fig. 1C). Our inability to
detect the endogenous UL79 proteins during infection is likely
due to either their extremely low levels of expression or their
unstable nature, similar to other HCMV proteins such as
pUL21a (17). Notably, the accumulation of the HA-tagged
UL79 protein overexpressed from transduced HFFs was also
reduced during infection relative to that in mock-infected cells,
suggesting that the turnover of UL79 proteins may be en-
hanced during infection (Fig. 1C). A more sensitive antibody
or assay will need to be developed in order to detect and
characterize endogenous UL79 proteins during HCMV infec-
tion.
Our systematic dissection of ADddUL79 infection in the
absence of Shield-1 allowed us to define the stage of the in-
fection cycle where UL79 functioned. Shield-1-dependent
rapid degradation/stabilization of ddFKBP-tagged proteins (3)
gave us a tool to define the requirement of UL79 in HCMV
infection in a nearly real-time manner (Fig. 2B). Treating in-
fected cells with Shield-1 for the first 48 hpi could not rescue
the growth of recombinant virus, whereas adding Shield-1 at
late times, even at 48 hpi, fully restored its growth (Fig. 2),
suggesting that UL79 was required at late stages of HCMV
infection. Consistent with the timing of its involvement in virus
infection, UL79 was expressed with early-late kinetics (Fig. 6)
and localized into viral replication compartments where viral
DNA replication and late gene transcription took place (Fig.
8). These spatial and temporal characteristics of UL79 support
its role in regulating the accumulation of viral late gene prod-
ucts at transcript levels (Fig. 3, 4, and 7).
Depletion of UL79 during HCMV infection was able to
uncouple viral DNA synthesis and viral late gene expression,
indicating that the former is not sufficient to promote the latter
(Fig. 4 and 5). For many DNA viruses, the temporal regulation
of viral gene expression is a common feature of their lytic
infection. For simian virus 40, the large T antigen plays an
essential role in the activation of viral promoters (5, 27), and
viral DNA replication attenuates in trans the repressor of viral
late promoters (58, 67). For adenovirus, both viral trans-acting
factors (23, 40) and viral DNA replication (53, 54) are required
for its late gene expression. Viral DNA replication facilitates
late gene expression directly (53) or indirectly by promoting
the expression of viral trans-acting factors (23) or recruitment
of cellular transcription factors to late promoters (54).
For herpesviruses, viral late gene expression has been stud-
ied mostly with herpes simplex virus (HSV) and murine gam-
maherpesvirus 68 (MHV-68). In HSV, DNA replication is
required in cis for activity of late promoters (26, 34). HSV
proteins, including ICP4, ICP8, and ICP27, are necessary for
efficient expression of late genes by interacting with the general
transcription machinery (19, 28, 47), and they facilitate the
assembly of transcription preinitiation complexes (8, 65). In
MHV-68, both viral DNA replication (12) and four viral pro-
teins, ORF18, ORF24, ORF30, and ORF34, are required for
late gene expression (2, 60, 61). HCMV UL79, UL87, and
FIG. 9. The UL79 protein is not detected in HCMV virions. A total
of 1 ! 107 HF-UL79HA or HF-vector cells were infected with
ADddUL79 in the presence or absence of Shield-1 at an MOI of 5.
Total cell lysates and cell-free virions were collected at 96 hpi. Cell-
free virions were then partially purified by ultracentrifugation through
a sorbitol cushion. Lysates of 1 ! 105 cells or 20% of total virion
samples harvested were loaded onto each lane of an SDS-polyacryl-
amide gel and analyzed by immunoblotting for MCP, IE1-72, pUL69,
and cellular PCNA. For the UL79 protein, twice as many virion sam-
ples were used in the experiment, and the protein was analyzed using
anti-HA antibody.
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Figure 2.10.  Immunoblot Analysis of viral ddFKBP Fusion Proteins.  Human fibroblast cells 
were infected with ADddUL71(A) and ADddUL77(B) recombinant viruses at MOI 3.0 in the 
presence and absence of 1µM Shield-1.  The cells were harvested at 48 and 96 hours post 
infection.  The accumulations of various ddFKBP-fusion proteins were analyzed by 
immunoblot analysis using anti-FKBP12 antibody. 
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Figure 7. Western Blot Analysis of ddFKBP Fusion Protein.  Human fibroblast cells were infected with 
ADinddFKBP-UL71(A), ADinddFKBP-UL77(B), and ADinddFKBP-UL79(C) recombinant viruses at MOI 3.0 in 
the presence and absence of 1µM Shield-1.  The cells were analyzed at 48 and 96 hours post infection by 
western blot using anti-FKBP antibody. 
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Table 2.1  Primers and probes used for RT-qPCR in Chapter 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
chloroform, precipitated with ethanol, and resuspended in nuclease-free water
(Ambion). Viral DNA was quantified by qPCR as previously described using a
TaqMan probe (Applied Biosystems) and primers specific for the HCMV UL54
gene (46). Cellular DNA was quantified with SYBR PCR master mix (Clontech)
and a primer pair specific for the human !-actin gene as previously described
(46). The accumulation of viral DNA was normalized by dividing the number of
UL54 gene equivalents by the number of !-actin gene equivalents. The accumu-
lation of wild-type viral DNA at 4 h postinfection (hpi) was arbitrarily set at 1.
Transcript accumulation was analyzed by reverse transcription coupled to
qPCR (RT-qPCR) as previously described (62). Total RNA was extracted using
the Trizol reagent (Invitrogen) and treated with the TURBO DNA-free reagent
(Ambion) to remove genomic DNA contaminants. cDNA was reverse tran-
scribed with random hexamer primers using the high-capacity cDNA reverse
transcription kit (Applied Biosystems). For IE1, cDNA was quantified by qPCR
using Maxima probe/Rox 2" qPCR master mix (Fermentas), and a TaqMan
probe (Applied Biosystems) and a primer pair specific for IE1. Alternatively,
cDNA was quantified using SYBR Advantage qPCR premix (Clontech) and
primer pairs specific for viral genes UL32, UL79, UL82, UL93-99, the ddFKBP
sequence of ddFKBP-UL79, or the GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase) cellular gene (16, 38, 57). All of the primer pairs and TaqMan probes
are listed in Table 1. cDNA from infected cells was used to generate a standard
curve for each gene examined. The standard curve was then used to calculate the
relative amount of a specific transcript present in a sample. The amounts of IE1,
UL32, UL79, UL82, and UL93-99 were normalized using GAPDH as an internal
control.
Protein analysis. Protein accumulation and subcellular localization were de-
termined by immunoblotting and immunofluorescence, respectively. For immu-
noblotting, cells were washed with phosphate-buffered saline and lysed in the
sodium dodecyl sulfate (SDS)-containing sample buffer. Virion proteins were
prepared by purifying cell-free virions from culture medium of infected cells by
ultracentrifugation through a sorbitol cushion and resuspending the cells in
SDS-containing sample buffer. Proteins were resolved by electrophoresis on an
SDS-containing polyacrylamide gel, transferred to a polyvinylidene difluoride
(PVDF) membrane, hybridized with primary antibodies, reacted with the HRP-
conjugated secondary antibody, and visualized by SuperSignal West Pico chemi-
luminescent substrate (Thermo Scientific) (62).
For immunofluorescence, cells grown on glass coverslips were fixed in 2%
paraformaldehyde, permeabilized with 0.1% Triton X-100 for 15 min, incubated
with a primary antibody, and subsequently labeled with an Alexa Fluor 488- or
568-conjugated secondary antibody (Invitrogen-Molecular Probes). Labeled cells
were also counterstained with TO-PRO-3 (Invitrogen-Molecular Probes) to vi-
sualize the nuclei. Finally, labeled cells were mounted on slides with Prolong
Gold antifade reagent (Invitrogen-Molecular Probes). Images were captured
using Zeiss LSM Image software with a Zeiss LSM 510 META confocal laser
scanning microscope.
RESULTS
Construction of a BAC-HCMV clone carrying the ddFKBP-
tagged UL79 and propagation of recombinant virus. The
HCMV UL79 ORF has been reported to be essential for
HCMV replication in fibroblasts (14, 63). To study the func-
tion of UL79 in virus infection, we adopted a protein-based
viral genetic approach (3, 20, 45). We constructed a recombi-
nant BAC-HCMV clone, pADddUL79, in which the annotated
UL79 coding sequence was tagged with a 110-amino-acid de-
stabilization domain derived from a mutant variant of the
human FKBP protein (ddFKBP) (3) at its N terminus (Fig.
1A). This recombinant clone was derived from the parental
BAC clone (pAD-GFP) which was also used to reconstitute
wild-type virus (ADwt) in this study (64). In cells infected with
recombinant virus (ADddUL79) that was derived from
pADddUL79, the ddFKBP-tagged UL79 protein was antici-
pated to be expressed but directed for rapid degradation by the
ddFKBP tag. However, the ddFKBP tag should be stabilized in
the presence of the synthetic chemical ligand Shield-1, and
therefore, the tagged protein should retain its activity. This
ddFKBP tagging approach offers some unique advantages for
creating mutant viruses. It abrogates protein products of es-
sential genes during virus infection without the need for cre-
ating null mutant virus and complementing cell lines. As only
one virus stock is needed for the comparative study of HCMV
infection in the presence or absence of a viral protein product,
it eliminates the need for creating marker rescued virus and
avoids the potential complication resulting from an altered
particle-to-PFU ratio in mutant virus. Finally, it provides evi-
dence that it is the protein encoded by the tagged ORF and not
other potential products derived from the UL79 locus that is
important for viral replication.
Transfection of pADddUL79 into human foreskin fibro-
blasts (HFFs) did not result in any detectable productive viral
infection when the cells were surveyed for 30 days. However,
when Shield-1 was added at a concentration of 1 #M, a cyto-
TABLE 1. Primers and probes used for RT-qPCR
Transcript qPCR reaction Primer sequence 6FAM-TAMRA TaqMan probe sequencea
IE1 TaqMan 5$-CAAGTGACCGAGGATTGCAA-3$ 5$-TCCTGGCAGAACTCGTCAAACAGA-3$
5$-CACCATGTCCACTCGAACCTT-3$
UL32 SYBR green 5$-GGTTTCTGGCTCGTGGATGTCG-3$ NA
5$-CACACAACACCGTCGTCCGATTAC-3$
UL79 SYBR green 5$-CCGCACGGGCAAATTCTCCT-3$ NA
5$-TGGTCCGAGACACCCAGGTTGTT-3$
UL82 SYBR green 5$-TGCTGATGTCTGCCGCGGTAC-3$ NA
5$-CGGGCACTGATCCTGACCGG-3$
UL93-99 SYBR green 5$-GTGTCCCATTCCCGACTCG-3$ NA
5$-TTCACAACGTCCACCCACC-3$
ddFKBP-UL79 SYBR green 5$-TGGAAACCATCTCCCCAGGAGA-3$ NA
5$-TCACCTCCTGCTTGCCTAGCAT-3$
GAPDH SYBR green 5$-CTGTTGCTGTAGCCAAATTCGT-3$ NA
5$-ACCCACTCCTCCACCTTTGAC-3$
a 6FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine; NA, not applicable.
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ABSTRACT 
In this chapter, we identified a unique mechanism in which human cytomegalovirus 
(HCMV) protein pUL79 acts as an elongation factor to direct cellular RNA polymerase II for 
viral transcription during late times of infection.  We and others previous reported that 
pUL79 and its homologues were required for viral transcript accumulation after viral DNA 
synthesis (28, 52).  We hypothesized that pUL79 represented a unique mechanism to regulate 
viral transcription at late times during HCMV infection.  To test this hypothesis, we analyzed 
the proteome associated with pUL79 during virus infection by mass spectrometry.  We 
identified both cellular transcriptional factors, including multiple RNA polymerase II (RNAP 
II) subunits, and novel viral transactivators, including pUL87, pUL92, and pUL95, as protein 
binding partners of pUL79.  Co-immunoprecipitation (co-IP) followed by immunoblot 
analysis confirmed the pUL79-RNAP II interaction, and this interaction was independent of 
any other viral proteins.  Using a recombinant HCMV virus where pUL79 protein is 
conditionally regulated by a protein destabilization domain ddFKBP, we showed that this 
interaction did not alter the total levels of RNAP II or its recruitment to viral late promoters.  
Furthermore, pUL79 did not alter the phosphorylation profiles of the RNAP II C-terminal 
domain, which was critical for transcriptional regulation.  Rather, nuclear run-on assay 
indicated that, in the absence of pUL79, RNAP II failed to elongate and stalled on viral DNA.  
pUL79-dependent RNAP II elongation was required for transcription from all three kinetic 
classes of viral genes (i.e. immediate-early, early, and late) at late times during virus infection.  
In contrast, host gene transcription during HCMV infection was independent of pUL79.  In 
summary, we have identified a novel viral mechanism by which pUL79, and potentially other 
viral factors, regulates the rate of RNAP II transcription machinery on viral transcription 
during late stages of HCMV infection. 
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INTRODUCTION 
Human cytomegalovirus (HCMV) is the prototypical beta-herpesvirus and a 
ubiquitous pathogen in the human population.  Upon primary infection, HCMV establishes a 
lifelong persistent and latent/recurrent infection in a host (15).  Even though HCMV infection 
is usually asymptomatic, it acts as an opportunistic pathogen and is the major cause of 
morbidity and mortality in immunocompromised individuals, including transplant recipients 
and AIDS/HIV patients (16).  Importantly, HCMV is the leading infectious cause of birth 
defects in newborns (6).  Furthermore, there is evidence for HCMV to act as a risk factor in 
the development of vascular diseases, such as atherosclerosis, transplant vascular sclerosis, 
and coronary restenosis after angioplasty surgery (23, 36, 42, 45, 60, 66, 79).  Recently, a 
role for HCMV has also been implicated in multiple forms of human cancers, where it may 
contribute to oncogenic transformation, onco-modulation, and tumor cell immune evasion (5, 
19, 31, 54). 
During lytic infection, HCMV genes are expressed in a highly ordered temporal 
cascade (reviewed in (3, 43, 62, 72)).  Viral transcripts accumulate with three kinetic classes, 
namely immediate-early, early, and late.  The HCMV major IE (MIE) genes UL123 (IE1) 
and UL122 (IE2) play critical roles in predisposing the cellular environment to infection and 
also act as transactivators to induce early gene transcription.  Many early genes encode 
proteins required for viral DNA synthesis (22, 24, 63).  The transcript accumulation of early 
genes is independent of viral DNA synthesis; however, the continued accumulation of a 
subset of these genes at late times is enhanced by the onset of viral DNA synthesis (61).  
Following viral DNA synthesis, late viral genes start to transcribe, which mostly encode 
structural proteins required for virus assembly and egress, ultimately leading to the release of 
infectious particles.  Previous studies have shown that the activation of both beta- and 
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gamma-herpesvirus late gene promoters is dependent on the origin of viral DNA synthesis 
(OriLyt) in cis (2, 17, 44).  This further supports the notion that late gene transcription is 
tightly coupled to viral DNA synthesis.  However, whether viral late gene expression is 
subjected to additional viral regulation remains poorly defined.  
Recently, we and others have demonstrated that HCMV encodes five essential 
proteins, UL79, UL87, UL91, UL92, and UL95, which are required for the expression of 
viral late genes after viral DNA synthesis (28, 48, 52).  Murine cytomegalovirus (MCMV) 
M79 and M92, homologs of HCMV UL79 and M92, respectively, are also required for late 
gene expression (9, 10).  Homologs of UL79, UL87, UL91, UL92, and UL95 are found in 
murine gammaherpesvirus 68 (MHV-68) (ORF18, ORF24, ORF30, ORF31, and ORF34, 
respectively), which have been shown to have similar functions (4, 30, 74, 75).  Epstein-Barr 
virus (EBV) BcRF1, a UL87 homolog, is a novel viral TATA-box binding protein with 
greater specificity for a non-classical TATA-box sequence (25, 76).  Intriguingly, these 
factors are conserved only in beta- and gamma-herpesviruses and have no known 
homologues in herpes simplex virus (HSV) (43, 48), suggesting a unique viral regulatory 
mechanism shared by these two herpesviral subfamilies.  However, the underlying 
mechanisms of how these viral factors regulate late gene expression are incompletely 
understood. 
During cytomegalovirus infection, viral genes are transcribed by cellular RNA 
polymerase II (RNAP II), a large multi-subunit enzyme.  Rpb1, the largest subunit of RNAP 
II, has a carboxy terminal domain (CTD) that contains repeats of the heptapeptide sequence 
of Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 (14).  The mammalian CTD is compromised of 52 
copies of heptapepetides (11).  This unstructured domain is strategically located adjacent to 
the mRNA exit channel of the enzyme.  This helps the CTD act as a scaffold to coordinate 
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interactions with proteins involved in different phases of transcription and allow for the 
coupling of transcription with other nuclear processes, such as mRNA maturation and 
chromatin modification (51, 58).  The amino acids within the CTD repeats are targets for 
post-translational modifications, including phosphorylation, glycosylation, ubiquitination, 
and cis-trans isomerization (13).  Different combinations of CTD modifications, known as 
the CTD codes, orchestrate the sequential recruitment of numerous factors during the 
transcription cycle (8). 
RNAP II activity is tightly regulated by phosphorylation of its CTD.  RNAP II is 
recruited to preinitiation complexes (PIC) in an unphosphorylated state (38).  Following the 
binding of RNAP II to a promoter, serine 5 residue of the CTD (Ser5) is rapidly 
phosphorylated by cdk7, the kinase subunit of the transcription factor TFII-H.  This facilitates 
the dissociation of RNAP II from the PIC (59), and also promotes the recruitment of capping 
and splicing factors as well as other histone modification complexes (51).  After dissociating 
from PIC, RNAP II proceeds to intrinsic pausing sites where it is halted by negative 
elongation factors (NELFs).  The onset of productive elongation requires the positive 
transcription elongation factor P-TEFb composed of cdk9 and cyclin T, which 
phosphorylates serine 2 residue (Ser2) of the CTD to produce stable elongation complexes 
(40).  Serine 2 phosphorylation also couples RNA synthesis with RNA processing by 
promoting the recruitment of splicing and polyadenylation factors (53).  At the 3’ end of the 
coding region, RNAP II dissociates from the DNA template and RNA transcript prior to 
transcript polyadenylation.  Specific phosphatases, Ssu72 and Fcp1, also dephosphorylate the 
CTD.  Thus, RNAP II is recycled as an unphosphorylated, initiation-competent form for 
another round of transcription (12, 35). 
HCMV utilizes RNAP II and the accompanying host machinery for transcription of 
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viral genes.  During early times of viral infection, RNAP II and other transcription machinery 
are recruited to early replication sites to drive viral IE and early gene expression (67).  The 
protein levels of RNAP II, including hyper-phosphorylated forms, increase as infection 
progresses (67, 69).  Treatment of infected cells with cdk inhibitors inhibits viral gene 
expression as well as viral replication (55).  During late stages of viral infection, cdk kinase 
and RNAP II-associated transcriptional machinery proteins continue to accumulate and 
relocate into the peri-replication center (69).  However, how RNAP II transcription 
machinery remains active on viral loci during late infection requires further investigation. 
In this chapter, we dissected the mechanism of CMV late gene expression by 
investigating the proteins that were associated with late transcription regulator pUL79 during 
HCMV infection.  We found that pUL79 interacted with a panel of viral and host proteins, 
including RNAP II, other novel late transcription regulators pUL87, pUL92, and pUL95, as 
well as components of the viral DNA replication complex.  We delineated the pUL79-RNAP 
II interaction and found that pUL79 bound to RNAP II in the nucleus independent of 
additional viral factors.  Mechanistically, pUL79 did not alter RNAP II protein levels or the 
phosphorylation profile of its CTD domain.  Instead, in the absence of pUL79, RNAP II 
stalled on viral DNA loci, including those of viral immediate-early, early, and late genes, but 
not those of host genes, during late times of infection.  This resulted in a significantly 
diminished elongation rate of RNAP II-driven transcription on viral loci.  We conclude that 
during late times of infection HCMV induces the formation of a unique transcriptional 
machinery in which pUL79 acts as an elongation factor to specifically drive RNAP II-
mediated transcription on the viral genome. 
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MATERIALS AND METHODS 
Plasmids and reagents.  pYD-C755 (i.e. pLKO) was a pLKO-based lentiviral vector 
(also referred as pLKO.DCMV.TetO.mcs in (20), a generous gift from Roger Everett, 
University of Glasgow Centre for Viral Research).  pYD-C751 (i.e. pLKO-HA-pUL79) was 
created by cloning a PCR fragment containing the UL79 coding sequence along with a N-
terminal hemagglutinin (HA) tag into the multiple cloning site of pYD-C755.  pYD-C744 
was derived from pGalK (71), and carried a cassette in which 3×FLAG tag was followed by a 
GalK/kanamycin dual expression cassette flanked by the Flp recognition target (FRT) 
sequence (49). 
The synthetic chemical ligand Shield-1 (Shld1) used to regulate the stability of 
ddFKBP-tagged proteins was purchased from Cheminpharma (Farmington, CT).  Benzonase 
was purchased from EMD Millipore.  The following primary antibodies were used in this 
study:  anti-beta actin (clone AC15, Abcam); anti-FLAG (clone M2, Sigma-Aldrich); anti-
HA (clone 16B12, Covance; clone 3F10, Roche); anti FKBP12 (clone 8/FKBP12, BD 
Biosciences); anti-Rpb1 (clone N-20 from Santa Cruz to detect total Rpb1; or clone 8WG16 
from Abcam to detect both total Rpb1 and unphosphorylated CTD form of Rbp1); anti-Rpb2 
(S-20, Santa Cruz); anti-Rpb1 phospho-CTD Ser5/Ser2 (clone H-14, Covance); anti-Rpb1 
phospho-CTD Ser5 (clone 3E8, Millipore); anti-Rpb1 phospho-CTD Ser2 (ab5095, Abcam); 
anti-CDK9 (clone H-169, Santa Cruz); anti-cyclin T1 (clone H-245, Santa Cruz); anti-pUL44 
(clone 10D8, Virusys); anti-IE1, anti-pp28, and anti-pp71 (generous gifts from Thomas 
Shenk, Princeton University). 
Cells and Viruses.  Primary human newborn foreskin fibroblasts (HFFs) and HEK-
293T cells were propagated in Dulbecco modified Eagle medium (DMEM) supplemented 
with 10% fetal calf serum, nonessential amino acids, sodium pyruvate, and penicillin-
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streptomycin.   
Three HCMV recombinant viruses, ADwt, ADddUL79, and ADflagUL79, were used 
in this study.  The wildtype virus ADwt was reconstituted from the BAC-HCMV clone 
pADwt (also referred as pAD-GFP in the previous study (52)).  pADwt carries the full-length 
genome of HCMV strain AD169, with the exception that it contains a simian virus 40 (SV40) 
early promoter-driven green fluorescent protein (GFP) gene in place of the viral US4-US6 
region that are dispensable for viral replication in HFFs (68, 77).  ADddUL79 was derived 
from ADwt using BAC recombineering, where the pUL79 coding sequence was fused to that 
of destabilizing domain ddFKBP (52). 
ADflagUL79 was reconstituted from the BAC clone pADflagUL79.  This BAC clone 
was derived from pADwt, and was constructed by using a linear recombination approach in 
the bacterial strain SW105 that contained an arabinose-inducible Flp gene for the transient 
expression of Flp recombinase (49).  Briefly, the cassette that carried 3×FLAG followed by 
the GalK/kanamycin dual marker was first generated by PCR from pYD-C744 with a pair of 
70-bp primers, so that the PCR-generated cassette was also flanked by 50-bp viral sequences 
immediately upstream or downstream of the 5’-end of the UL79 coding sequence.  The 
cassette was recombined into pADwt at the 5’-end of the UL79 coding sequence by using 
linear recombination.  The GalK/kanamycin marker was subsequently removed by Flp-FRT 
recombination (49).  The final clone pADflagUL79 contained the 3×FLAG sequence along 
with a small FRT site fused in frame at the 5’-terminus of the UL79 coding sequence (Figure 
3.1A). 
To reconstitute virus, 2µg of the BAC-HCMV DNA and 1µg of the pp71 expression 
plasmid were transfected into HFF cells by electroporation (77), and the culture medium was 
changed 24 hours later.  For reconstitution of ADddUL79 virus, Shld1 was added every 48 
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hours to maintain the concentration at 1 µM.  Reconstituted virus was harvested by collecting 
cell-free culture supernatant when the entire monolayer of cells was lysed.  To produce virus 
stocks, cell-free culture supernatants were collected from HFFs infected at an MOI of 0.01.  
Viruses were pelleted by ultracentrifugation through a 20% D-sorbitol cushion at an average 
relative centrifugal force of 53,000 × g for 1 hour, resuspended in DMEM with 10% tissue 
fetal calf serum, and saved as viral stocks.  HCMV titers were determined by 50% culture 
infectious dose (TCID50) assay in HFFs (52). 
Transient transfection.  Four µg of plasmid DNA and 12 µl polyethylenimine (PEI) 
(1mg/ml, Polysciences) were mixed with 100 µl OPTI-MEM (Invitrogen) and incubated at 
room temperature for 10 minutes.  The mixture was then added to 900 µl complete medium 
containing 10% fetal calf serum, and applied to 5×106 HEK-293T cells that were seeded one 
day before.  Cells were incubated for 4 hours before medium was changed. 
Analysis of Immunoprecipitation, Mass Spectrometry, and Immunoblot.  For 
total cell lysates, immunoprecipitation was performed using a protocol modified from 
previous studies (56, 64, 65).  In brief, HFF cells (5×107) were infected with HCMV 
ADflagUL79 or ADwt at a multiplicity of infection (MOI) of 3.  At 72 hpi, cells were 
collected, rinsed twice with cold phosphate-buffered saline (PBS), and lysed in 2ml EBC2 
buffer (50 mM Tris [pH 8.0], 300 mM NaCl, 0.5% NP40) supplemented with protease and 
phosphatase inhibitors.  Cell lysates were then supplemented with 250 unit (U) Benzonase 
nuclease (Millipore), incubated at 4°C for 15 minutes.  One aliquot of cell lysates was saved 
as the input control and boiled in the LDS sample buffer in the presence of sample reducing 
agent (Novex).  The remainder was clarified by centrifugation at 10,000 × g at 4°C for 15 
minutes.  The supernatant was incubated with protein A-dynabeads (Novex) conjugated with 
antibody to FLAG (M2) or Rpb1 (N-20) together with an additional 250U of Benzonase at 
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4°C overnight.  In addition, to confirm the nuclease activity of Benzonase, an aliquot of the 
supernatant was analyzed on a 0.8% agarose gel containing 100 µg/ml ethidium bromide for 
the detection of DNA/RNA.  The following day the beads were washed three times with 1 ml 
EBC2 buffer and once with EBC2 buffer without NP40.  The immuneprecipitants were 
eluted by boiling in reducing sample buffer for 5 minutes.  For nuclear extracts, 
immunoprecipitation was performed using the Nuclear Complex Co-IP kit according to the 
manufacturer’s instructions (Active Motif). 
For mass spectrometry analysis, proteins precipitated by anti-FLAG antibody was 
resolved on a NuPAGE 4-12% gradient gel (Novex) and subsequently stained using a 
ProteoSilver Silver Stain kit (Sigma-Aldrich) according to the manufacturer’s instruction.  
Protein bands unique to ADflagUL79-infected sample were extracted.  In addition, gel bands 
from the ADwt-infected sample with migrating positions corresponding to those of 
ADflagUL79-specific bands were also extracted as negative controls.  Extracted gel samples 
were submitted to the Keck Mass Spectrometry and Proteomics Facility (School of Medicine, 
Yale University) for liquid chromatography (LC)-mass spectrometry analysis for protein 
identification. 
Protein amounts were determined by immunoblot analysis as previously described 
(52).  In brief, proteins were resolved on an SDS polyacrylamide gel, transferred to a 
polyvinylidene difluoride (PVDF) membrane, hybridized with a primary antibody, reacted 
with the horseradish peroxidase-conjugated secondary antibody, and visualized using 
chemiluminescent substrate (Thermo Scientific).   
Chromatin immunoprecipitation (ChIP).  The ChIP was performed using the 
MAGnify chromatin-immunoprecipitation system (Life Technologies) and reagents provided 
in the kit according to the manufacturer’s protocol with modifications.  2×106 HFFs were 
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infected with ADddUL79 at an MOI of 3.0 in the presence or absence of Shld1.  At 72 hours, 
infected cells were washed twice with PBS, trypsinized, and crosslinked with 1% 
formaldehyde at room temperature with mixing for 10 minutes.  Glycine was added to the 
final concentration of 125 mM and incubated at room temperature for 5 minutes to stop the 
cross-linking reaction.  Cells were collected by centrifugation at 4°C, 200×g for 10 minutes, 
washed twice in ice-cold PBS, and lysed in 100 µl lysis buffer with protease inhibitors.  
Chromatins were shared into 200-500 bp fragments by cup-horn sonication in ice water at 30-
second pulse and 60% output with 40-second interval for 70 times (Branson Sonifier 450).  
Samples were gently votexed every five sonication cycles and allowed to cool in ice water for 
additional 2 minutes.  Lysates were cleared by centrifugation (20,000×g, 15 minutes; 4°C) 
and stored as 20-µl aliquots.  To confirm the size of sheared chromatin fragments, one 20-µl 
aliquot was treated with RNase A at 37°C for 1 hour and de-crosslinked by protease K 
treatment overnight.  DNA was purified and analyzed by agarose gel electrophoresis (data 
not shown).   
To immunoprecipitate protein-bound chromatin fragments, each 20-µl aliquot was 
diluted in dilution buffer with protease inhibitors, and first incubated with 40 µl BSA-
preblocked protein A/G Dynabeads to pre-clean for 2 hours.  Beads were removed, and one 
tenth volume of the supernatant was saved as the input sample.  The remainder of the 
supernatant was incubated with appropriated antibodies to generate protein-antibody 
complexes or with IgG (negative control) (Table 3.2) at 4°C for 16 hours.  Forty µl BSA-
preblocked protein A/G Dynabeads (Invitrogen) was added to the samples and incubated at 
4°C for another 1.5 hours to immunoprecipitate the complexes.  Beads were collected, 
washed twice with IP Buffer 1 and three times with IP Buffer 2.  Protein-antibody complexes 
were eluted from Dynabeads by incubation with reverse crosslinking buffer with proteinase 
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K at 55°C for 15 minutes.  Dynabeads were removed, and crosslinking of protein-antibody 
complexes in the supernatant were reversed by incubation at 65°C for 15 minutes.  In 
addition, the input sample was also treated with the reverse crosslinking buffer in the same 
procedure to reverse crosslinking.  Both input and immunoprecipitated DNAs were isolated 
by DNA purification on magnetic beads.  DNA fragments were quantified by quantitative 
real-time PCR (qPCR) using SYBR Select Mix (Invitrogen) kit or Taqman Fast Advanced 
Master Mix kit (Invitrogen).  The sequences of primers and Taqman probes are listed in 
Table 3.3. 
Nuclear run-on assay.  The protocol of nuclear run-on assay was adapted from 
previous studies with modifications (18, 50, 57).  1×107 HFFs were infected with ADddUL79 
at an MOI of 3 in the presence or absence of Shld1.  At 72 hpi, cells were washed twice with 
PBS, trypsinized, collected by centrifugation (4°C, 270×g), and washed twice with cold PBS 
again to remove residual calcium and magnesium.  To extract nuclei, cell pellets were 
resuspended in 4 mL cell lysis buffer (10 mM Tris-HCl, pH 7.2, 3 mM MgCl2, 10 mM NaCl, 
150 mM sucrose, and 0.5% NP40) for 5 minutes on ice.  Extracted nuclei were collected by 
centrifugation (4°C, 170×g) and gently washed with cell lysis buffer to remove NP40.  Pellets 
were resuspended in 300 µl freezing buffer (50 mM Tris-HCl, pH 8.3, 40% glycerol, 5 mM 
MgCl2, and 0.1 mM EDTA), washed once with 1× run-on reaction buffer (20 mM Tris-HCl, 
pH 7.5, 10 mM MgCl2, 150 mM KCl, and 20% (v/v) glycerol).  To perform run-on assay, 107 
nuclei were incubated in 100 µl 1× run-on reaction buffer with ATP, CTP, GTP (0.5 mM 
each), and 0.2 mM biotin-16-UTP (Invitrogen) at 29°C for 30 minutes.  The reaction was 
stopped by snap freezing in liquid nitrogen.  As negative controls, run-on reactions were also 
performed with UTP instead of biotin-16-UTP.  To isolate biotin-labeled run-on transcripts, 
streptavidin-coated Dynabeads (Dynabeads MyOne Streptavidin C1, Invitrogen) were 
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resuspended in binding buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, and 2 M NaCl), and 
mixed with an equal volume of run-on transcripts.  The samples were incubated at 42 °C for 
20 minutes and then at room temperature for 1.5 hours.  Beads were collected, and washed 
twice with 15% formamide and three times with 2× standard saline citrate (Invitrogen).  
Biotinylated RNAs on the beads were reverse transcribed to generate cDNA using Supercript 
VILO cDNA Synthesis Kit (Invitrogen), and quantified by reverse transcription-coupled 
qPCR (RT-qPCR) analysis.  The relative transcript amounts were normalized to those of 18S 
rRNA (that is transcribed by RNA polymerase I (RNAP I) so is an unbiased internal control 
for RNAP II activity).  In addition, total RNA of infected cells was also isolated separately by 
TRIzol extraction (Invitrogen) and the amounts were determined by RT-qPCR analysis (see 
Table 3.3 for primer sequences).   
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RESULTS 
Identification of pUL79-interacting proteins 
To investigate proteins associated with pUL79, we first generated a recombinant 
HCMV in which the UL79 coding sequence was tagged with the 3×FLAG sequence 
(ADflagUL79) so that protein complexes containing pUL79 in infected cell lysate could be 
isolated by immunoprecipitation (IP) with an anti-FLAG antibody (Figure 3.1A).  Both 
growth and protein expression profile (Figures 3.1B and 3.1C) of ADflagUL79 was 
indistinguishable from those of wildtype AD169 strain (ADwt) in human foreskin fibroblasts 
cells (HFFs).  These results indicate that the addition of 3×FLAG tag to the N-terminus of the 
UL79 coding sequence does not compromise the function of pUL79. 
To identify proteins that interacted with FLAG-pUL79, lysates from HFF cells 
infected with virus ADflagUL79 or ADwt (negative control) were collected at 72 hours post 
infection (hpi) and immunoprecipitated with the anti-FLAG antibody.  Immunoprecipitated 
proteins were resolved by SDS-PAGE and visualized by silver staining (Figure 3.1D).  
Protein bands unique to ADflagUL79 were extracted and their identities were determined by 
mass spectrometry.  For the negative control, we also extracted gel bands from the ADwt 
sample with migrating positions corresponding to those of ADflagUL79-specific protein 
bands as negative controls for mass-spectrometry analysis.  The full set of proteins that were 
identified by this approach and unique to ADflagUL79 is listed in Table 3.1. 
These pUL79-interacting proteins could be categorized into several functional groups.  
Most notably, four out of twelve core subunits of human RNA polymerase II (RNAP II), 
namely Rpb1, Rpb2, Rpb3, and Rpb5, were identified (Table 3.1).  Rpb1 is the largest 
subunit of RNAP II and its C-terminal domain (CTD) plays a critical role in transcription 
regulation by interacting with various transcriptional factors.  Second, several viral proteins 
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that are conserved among beta- and gamma- herpesviruses, including pUL87, pUL95, 
pUL49, and pUL92, were found in the pUL79-protein complexes.  pUL87, pUL92, and 
pUL95 (shown in Table 3.1), together with pUL79, were required for viral late gene 
expression and reported to be recruited to the viral pre-replication complexes(10, 28, 52).  
These data together suggest that pUL79 interacts with other viral regulatory proteins involved 
in late gene expression during HCMV infection.  Third, proteins that were involved in 
HCMV DNA synthesis and shown to bind to viral lytic origin of replication (OriLyt) (32), 
including pUL44, pIRS1, and pUL112/113, were also found in pUL79 protein complexes.  
Copurification of pUL79 and viral DNA replication factors suggests that pUL79 may have a 
role in coordinating viral DNA synthesis and late gene expression.  Finally, several cellular 
proteins involved in protein translation, such as ribosomal protein subunits and elongation 
factor 1-alpha1, were co-purified with pUL79. 
In the chapter, we focused on the interaction between pUL79 and RNAP II subunits.  
As RNAP II transcribes viral genes during infection, we hypothesized that pUL79 interacted 
with RNAP II to modify and promote its activity for viral transcription during late times of 
infection. 
 
pUL79 interacts with the RNAP II complex 
To further investigate the association of the RNAP II complex with pUL79, we first 
validated this interaction by immunoprecipitation analysis.  HFFs were infected with either 
ADflagUL79 or ADwt (negative control), cell lysates were collected at 72 hpi, and proteins 
were immunoprecipitated by using antibodies against RNAP II or FLAG, followed by 
immunoblot analysis (Figure 3.2).  Two RNAP II subunits, Rpb1 and Rpb2, were co-
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immunoprecipitated with FLAG-pUL79 but not with ADwt-infected samples (Figure 3.2A).  
In a reciprocal experiment, an anti-Rpb1 antibody co-immunoprecipitated not only the RNAP 
II complex (indicated by Rpb1 and Rpb2) in both ADflagUL79- and ADwt- infected samples, 
but also FLAG-pUL79 in ADflagUL79-infected samples (Figure 3.2B).  Taken together, 
these results indicate that pUL79 is associated with the RNAP II complex during viral 
infection. 
The RNAP II complex binds to both DNA and RNA fragments.  It was possible that 
the observed interaction of pUL79 with RNAP II was indirect, the result of the association of 
both proteins with the same DNA or RNA fragment.  To determine if nucleic acids were 
required for the pUL79-RNAP II interaction, cell lysates were treated with a nonspecific 
nuclease (Benzonase) prior to immunoprecipitation (65).  Benzonase treatment was effective, 
reducing RNA/DNA levels to undetectable levels in ethidium bromide-stained agarose gel 
electrophoresis analysis (Figure 3.2A and Figure 3.2B).  In the presence of nuclease, pUL79, 
Rpb1, and Rpb2 remained co-immunoprecipitated in ADflagUL79-infected lysates (Figure 
3.2A and 3.2B).  Taken together, these results indicate that pUL79 and RNAP II associate 
with one another, and that this association is not mediated by nucleic acids. 
We then determined whether the pUL79-RNAP II interaction could form independent 
of additional viral factors.  To achieve this, we transfected HEK-293T cells with a plasmid 
expressing HA-tagged pUL79 or an empty vector plasmid.  pUL79 contains a PY-nuclear 
localization signal directing it into the nucleus (70) and is located in viral replication 
compartments during infection (28, 52).  Therefore, we extracted nuclear lysates of 
transfected cells, and performed coimmunoprecipitation analysis to examine the pUL79-
RNAP II interaction using either an anti-HA antibody or anti-Rpb1 antibody in the presence 
of nuclease.  As anticipated, HA-pUL79 was present in the nuclear extracts (Figure 3.2C and 
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3.2D).  Anti-HA antibody immunoprecipitated HA-pUL79 together with Rpb1, particularly 
the Rpb1 CTD phosphorylated at Serine 2 (pSer2-CTD) (Figure 3.2C).  As pSer2-CTD is a 
marker of RNAP II undergoing transcriptional elongation, this result suggests that pUL79 
may interact with RNAP II during the transcription cycle to modulate its elongation.  
Reciprocal coimmunoprecipitation using an anti-Rpb1 further confirmed the association of 
RNAP II with pUL79 (Figure 3.2D).  Together, these results indicate that pUL79 interacts 
with RNAP II independent of other viral factors.  The presence of pSer2-CTD in the pUL79-
RNAP II complex also suggests that pUL79 may regulate the elongation activity of RNAP II. 
 
pUL79 does not alter protein accumulations of RNAP II 
A previous study found that HCMV promoted the accumulation of RNA polymerase 
II at late times during infection (69).  Various isoforms of phosphorylated RNAP II, 
including pSer2-CTD and pSer5-CTD (i.e. CTD phosphorylated at Serine 5, a hallmark of 
successful transcription initiation) also accumulate at these late times (67, 69).  However, the 
mechanism of how HCMV regulates these RNAP II-mediated transcriptional events is not 
clear.   
To test if the pUL79-RNAP II association could stabilize the RNAP II complex to 
increase its protein levels, we measured RNAP II protein accumulation during HCMV 
infection in the presence or absence of pUL79 protein.  We have previously constructed a 
recombinant HCMV virus ADddUL79 in which the UL79 coding sequence was tagged with 
the highly unstable ddFKBP domain (52).  This allowed us to abrogate pUL79 function by 
targeting it for rapid degradation, or maintain its function by stabilizing the protein with the 
synthetic ligand Shield-1 (Shld1) (52).  Here, we infected HFF cells with ADddUL79 in the 
presence or absence of Shld1, and analyzed infected cell lysates by immunoblotting at 
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various times post infection.  In the presence of Shld1, ddFKBP-pUL79 was detected at 72 
hpi using the antibody recognizing the ddFKBP epitope, whereas in the absence of Shld1, no 
protein was detected (Figure 3.3).  To confirm this regulation of pUL79 activity, we also 
examined expression profiles of representative viral immediate-early (IE1), early (pUL44), 
and late (pp71) proteins.  In the presence of pUL79, all three classes of viral proteins were 
accumulated with expected kinetics (Figure 3.3).  In the absence of pUL79, immediate-early 
and early proteins accumulated normally but the accumulation of the late protein was 
dramatically reduced (Figure 3.3).  These results were consistent with the previous study 
(52), and validated the effectiveness of Shld1-mediated regulation of pUL79 activity in this 
study.  Importantly, the protein levels of Rbp2 and Rpb1 (both total Rpb1 and various CTD-
phosphor isoforms) increased as expected when infection progressed (67, 69), but the 
accumulations were independent of the presence or absence of pUL79 (Figure 3.3).  
Together, these results indicate that total RNAP II as well as its CTD modified forms 
accumulate during viral infection in a pUL79-independent manner. 
 
pUL79 alters RNAP II occupancy at viral loci 
A previous study showed that MHV-68 ORF30 and ORF34, homologues of HCMV 
UL91 and UL95, respectively, were required for the recruitment of RNAP II to the viral late 
promoters (75).  Like ORF30 and ORF34, both UL91 and UL95 were reported to be essential 
for late gene expression (28, 48).  In this study, we identified pUL95 as a protein partner of 
pUL79 (Table 3.1).  Therefore, we hypothesized that pUL79 formed a complex with pUL95 
and other binding partners to recruit RNAP II to promote assembly of the transcription 
initiation complex at viral late promoters. 
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To test this, we determined the occupancy of RNAP II on viral late promoters with or 
without pUL79 during infection using chromatin immunoprecipitation (ChIP) assay.  HFFs 
were infected with ADddUL79 in the presence or absence of Shld1, chromatin fractions from 
infected cells was collected at 72 hpi and analyzed by ChIP assay using a rabbit anti-RNAP II 
antibody.  The amounts of input and output (immunoprecipitated) DNA were measured by 
quantitative real-time PCR (qPCR) analysis using primers specific to the promoter or 
transcript regions of viral genes or cellular housekeeping gene GAPDH (Table 3.3).  The 
results were presented as relative output-to-input ratios to account for the percentages of 
host/viral genomes occupied by RNAP II during viral infection (Figure 3.4).  The levels of 
viral and cellular DNA immunoprecipitated by Rbp1 antibody were readily detectable 
whereas DNA immunoprecipitated by control IgG was minimal, indicating the specific 
binding of Rbp1 to the DNA sequences detected in this assay.  However, to our surprise, the 
occupancy of Rpb1 at promoter or transcript regions of viral genes was not reduced in the 
absence of pUL79 (Figure 3.4).  Instead, without pUL79, Rpb1 levels on viral DNA were ~2-
2.5 fold higher than those with pUL79.  Importantly, during late times of infection (72 hpi), 
elevated Rpb1 accumulation occurred not only on the loci of viral late genes (UL32 and 
UL75), it also occurred on those of viral immediate-early genes (MIE) and early genes 
(UL54) (Figure 3.4).  Moreover, this increased association of RNAP II with viral DNA 
occurred at both promoter regions and transcript regions.  By comparison, Rpb1 occupancy 
on the host gene GAPDH was not altered by pUL79.  Taken together, these results indicate 
that pUL79 regulates the occupancy of RNAP II, but not its recruitment, onto viral loci 
during late times of viral infection. 
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pUL79 does not alter a particular phosphorylated form of the RNAP II CTD domain 
Next we wanted to determine how dysregulated elevation in the occupancy of RNAP 
II contributed to its diminished ability to transcribe viral genes when pUL79 was abrogated.  
Specifically, we wanted to determine which stage of the RNAP II transcription cycle (i.e. 
initiation, elongation, or termination) was altered by pUL79 by ChIP analysis using 
antibodies recognizing various forms of RNAP II CTD modifications.  In a transcription 
cycle, Ser5 of RNAP II CTD is rapidly phosphorylated (pSer5-CTD) to facilitate the 
dissociation of RNAP II from the promoter and recruitment of RNA capping and splicing 
factors.  After that, pSer5 CTD levels decrease with concomitant Ser2 phosphorylation 
(pSer2-CTD) to facilitate efficient transcription elongation.  At 72 hpi, we found that both 
pSer5-CTD and pSer2-CTD levels significantly increased on viral loci in the absence of 
pUL79 compared to those in the presence of pUL79 (Figure 3.5A).  However, the increase of 
unphosphorlyated CTDs on viral loci also paralleled that of phosphorylated CTD (Figure 
3.5A).  Therefore pUL79 abrogation appeared to elevate all forms of CTD modifications 
tested at viral loci. 
To more specifically determine whether the elevated accumulation of RNAP II on 
viral DNA arose from a specific CTD modification in the absence of pUL79, we normalized 
the ChIP occupancy values of pSer5-CTD, pSer2-CTD, and unphosphorylated CTD to that of 
total RNAP II.  Occupancies of various CTD modifications were proportional to that of total 
RNAP II, and we found no evidence for the preferential occupancy of a particular CTD 
modification on any viral locus examined (Figure 3.5B).  Therefore, elevated RNAP II 
occupancy in the absence of pUL79 was unlikely due to the dysregulation of CTD 
phosphorylation.  Consistently, protein levels of CTD kinases (Cyclin T1 and CDK9) and 
CTD phospho-isoforms (pSer2-CTD, pSer5-CTD, pSer5/pSer2-CTD) were not altered by the 
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presence or absence of pUL79 (Figure 3.3).  These results together indicate that pUL79 is not 
involved in phosphorylation of RNAP II CTD, and suggest that without pUL79, RNAP II 
simply stalls during the transcription cycle, resulting in its elevated accumulation at viral loci. 
 
pUL79 alters the rate of transcriptional elongation at viral loci 
Based on the above results, we hypothesized that pUL79 was required for efficient 
elongation of RNAP II-driven transcription at viral loci.  To test this, we determined RNAP II 
elongation activity using nuclear run-on (NRO) assay.  The NRO assay allowed us to 
monitored the contribution of RNAP II transcriptional activity to transcript levels 
independent of the effect of RNA stability (57).  To do this, HFF cells were infected with 
ADddUL79 in the presence or absence of Shld1, and the nuclei of infected cells were isolated 
and analyzed by NRO assay.  Additionally, total RNA was also harvested to monitor the total 
transcript accumulation. 
We found that in the absence of pUL79, the run-on RNA levels of both MIE and late 
genes (UL99 and UL32) were reduced at 72 hpi to approximately 40% of those in the 
presence of pUL79 (Figures 3.6A, 3.6D, and 3.6E).  The run-on RNA levels of early genes 
(UL44 and UL54) without pUL79 were also reduced to approximately 60% of those with 
pUL79 (Figures 3.6B and 3.6C).  As RNAP II transcribes at the rate of 1.3-4.0 kb/minute 
(39), our NRO assay was performed for 30 minutes, long enough for RNAP II to transcribe 
all the viral genes tested.  However, without pUL79, RNAP II still failed to transcribe viral 
genes at the levels comparable to those in pUL79-containing controls.  Considering the 
increased accumulation of RNAP II at the viral loci in the absence of pUL79, we concluded 
that RNAP II requires pUL79 to efficiently elongate on the viral DNA. 
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As a control, we also examined the run-on RNA levels of host genes GAPDH and 
RPL30 (which encodes a 60S ribosomal protein).  Both genes possess a pattern of histone 
modifications typical of permissive chromatin, similar to those associated with most CMV 
viral loci during late times of infection (47).  In contrast to viral genes, the run-on RNA levels 
of both GAPDH and RPL30 were not altered by pUL79 (Figures 3.6F-3.6G).  This is 
consistent with ChIP analysis where the occupancy of RNAP II at GAPDH was found 
unaltered in the absence of pUL79 (Figure 3.4), and indicates that RNAP II does not stall at 
host genomic loci even without pUL79.  Therefore, pUL79 is specifically required for 
efficient transcription of viral genes but not host genes. 
Taken together, our results from NRO assay provide definitive evidence that pUL79 
positively regulates the transcription rates of viral genes but not those of host genes.  In the 
absence of pUL79, RNAP II may still elongate at viral loci but does so at a much slower pace 
at late times, and ultimately fails to support productive viral gene transcription and viral 
progeny production. 
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DISCUSSION 
In this chapter, we discovered a novel regulatory mechanism of viral transcription 
mediated by HCMV protein pUL79.  We identified cellular RNA polymerase II (RNAP II) as 
a key factor that interacted with pUL79.  This interaction did not alter the overall 
accumulation of total RNAP II or its various phospho-isoforms during viral infection.  
Rather, our data suggest that this interaction allowed pUL79 to act as a virus-encoded 
elongation factor to stimulate transcriptional elongation activity of RNAP II on viral loci.  
Without pUL79, RNAP II elongation failed to proceed efficiently and stalled on the viral 
genome.  This caused slow turnover and excessive amount of RNAP II accumulation on viral 
loci.  Ultimately this led to the failure to productive viral late transcription and progeny 
production. 
This pUL79-mediated regulation occurred at viral loci of all three kinetic classes 
(immediate-early, early, and late) at late times during infection.  Previously, when total viral 
transcripts were analyzed at early times during infection, both immediate-early and early 
transcripts accumulated efficiently before pUL79, which was a late protein, could be 
expressed (28, 52).  Some of these transcripts could be stable and persist until late times of 
infection.  When overall transcript accumulations were analyzed, the presence of pre-existing 
transcripts rendered it difficult to reveal the effect of pUL79 on transcription of immediate-
early and early genes at late times during infection.  NRO assay could measure relative 
transcription elongation rates at specific gene locus at defined times post infection.  It 
allowed us to show that in fact pUL79 had the potential of driving transcription of many 
more viral genes than previously expected during late times of viral infection.  A systemic, 
global run-on analysis of virally infected cells will further define the scope of viral gene 
transcriptions regulated by pUL79. 
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How does pUL79 modulate the elongation rate of RNAP II?  It is possible that pUL79 
enhances promoter clearance, a step in which RNAP II transfers from the initiation state to 
the elongation state (Figure 3.7A).  During the transcription cycle, RNAP II is recruited to 
promoters by cellular TATA-box binding protein (TBP) and other general transcription 
factors (GTFs) to form the pre-initiation complexes (PIC).  The PIC places RNAP II at 
transcription start sites, denatures DNA, and positions DNA into the RNAP II active site for 
transcription (7).  Once transcription initiates, RNAP II dissociates from PIC and recruits 
elongation factors for efficient transcription.  The dissociation of RNAP II from PIC is 
mediated by TFIIH and other cellular kinases to facilitate exchange between initiation factors 
and elongation factors (1, 78).  Inefficient dissociation from PIC reduces the rate of RNAP II 
elongation, resulting in the failure to transcribe genes (1).  Several herpesviral proteins have 
been reported to act as viral transcription initiation factors to form a unique viral PIC.  For 
example, the homologues of HCMV UL87 in gamma-herpesviruses were reported to encode 
viral TBPs and regulate late transcript accumulation (2, 25).  MHV68 ORF30 and ORF34, 
homologues of HCMV UL91 and UL95, were shown to be required for RNAP II recruitment 
to viral late promoters (75).  EBV Rta, a homolog of CMV UL112/113, was found to 
associate with viral late promoters during late times of viral infection (26).  These viral 
factors might participate in viral PIC assembly by mediating RNAP II promoter positioning.  
During HCMV infection, the recruitment of RNAP II to viral promoters was not reduced in 
the absence pUL79, suggesting that pUL79 was not required for transcription initiation 
(Figure 3.4).  However, the elongation rate of RNAP II at viral loci was reduced drastically, 
suggesting that pUL79 was essential for a transcription step downstream of initiation (Figure 
3.6).  Strikingly, pUL79 co-purified with pUL87 and pUL95, two viral factors potentially 
involved in viral PIC assembly (Table 3.1).  As the viral PIC complex may not be recognized 
by host dissociation factors, it is possible that pUL79 plays a role in the release of RNAP II 
!! 89!
from viral PIC prior to elongation (Figure 3.7A).  To test this, further analysis is required to 
determine the composition of RNAP II/viral PIC as well as their distribution on the viral 
DNA.  
It is also possible that pUL79 plays a role in epigenetic regulation to modulate viral 
transcription (Figure 3.7B).  During HCMV infection, viral DNA is chromatinized and 
undergoes histone modifications to facilitate gene expression (46).  In particular, upon the 
onset of viral DNA replication, newly synthesized viral DNA is wrapped with histone 3 with 
lysine 4 methylation (H3K4me2), a modification that favors active transcription, suggesting 
the potential involvement of epigenetic regulation in viral late transcription (47).  Even 
though pUL79 was not required for methylating H3K4 (47), the possibility remains that 
pUL79 may act as an epigenetic reader to recognize histone modifications unique to viral 
DNA, and unwrap viral DNA packaged by histones to facilitate RNAP II elongation (Figure 
3.7B). 
How does pUL79 specifically regulate transcription of viral loci? In this chapter, we 
showed that pUL79-mediated transcriptional regulation was limited to viral but not host 
genes (i.e. GAPDH and RPL30).  This specificity may be partially due to the localization of 
pUL79 during infection as pUL79 is enriched in viral replication compartments where late 
viral transcription occurs (52).  In addition, late promoters of beta- and gamma-herpesviruses 
contain a non-canonical TATA box sequence (25).  EBV BcRF1, the homologue of HCMV 
pUL87, is a viral TATA-box binding protein which preferentially binds to this non-canonical 
TATA box over the canonical sequence.  This suggest that viral transcription machinery 
directs RNAP II to viral late promoters during late stages of viral infection (25).  In HCMV, 
several characterized viral late promoters also contain the same non-canonical TATA 
sequences (21, 29, 33, 37, 41, 73).  Therefore, pUL79 may also act as viral specific TATA-
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box binding protein.  However, in this chapter, we observed an overall decrease in 
transcription rates among all three kinetic classes of viral loci during late times of infection 
(Figure 3.6).  Further analysis is needed to understand how pUL79 can regulate the rate of 
viral transcription regardless of the structures of gene promoters. 
In this chapter, we found that pUL79 also co-purified with other viral regulators of 
HCMV late gene expression, suggesting that pUL79 may interact with these regulators to 
form complexes during viral infection (Table 3.1).  It is not known whether these viral 
regulators use similar mechanisms to regulate viral transcription.  For example, pUL91 and 
pUL92 were shown to specifically regulate only true late genes (48).  It is possible that these 
regulators have conserved functions and yet still possess different specificities.  In addition, 
pUL79 also co-purified with viral DNA replication factors (Table 3.1).  Previously we have 
shown that pUL79-mediated viral transcription requires the onset of viral DNA synthesis 
(52).  Expression of neither pUL79 alone nor the combination of all known late gene 
regulators alters the expression kinetics of viral genes, especially viral late genes (48, 52).  
Therefore, it is also possible that viral DNA synthesis events predispose viral DNA to late 
transcription via interactions between replication factors and pUL79. 
In conclusion, we have used a systematic proteomic approach to elucidate the 
mechanism underlying the activity of HCMV late gene expression regulator pUL79.  pUL79 
interacts with RNAP II to modulate its transcription rate at viral loci during late times of viral 
infection.  This unique viral mechanism is potentially conserved among beta- and gamma- 
herpesviruses, and provides insight into the design of novel antivirals targeting steps after 
viral DNA synthesis.
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FIGURES 
 
Figure 3.1.  Identification of pUL79 interacting proteins.  (A) Schematic diagram for 
creating pADflagUL79, the recombinant HCMV BAC clone used to produce virus 
ADflagUL79.  A cassette that contained a 3×FLAG tag followed by the FRT-bracketed 
GalK/kanamycin dual selection marker was amplified by PCR and recombined into the 
wildtype HCMV BAC clone (pADwt) at the 5’ terminus of the UL79 coding sequence.  The 
selection marker was then removed by Flp/FRT recombination.  The final clone, 
pADflagUL79, carried the UL79 coding sequence tagged at its 5’ terminus with 3×FLAG.  
(B) Single step viral growth analysis.  HFF cells were infected with HCMV recombinant 
BAC recombineering 
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virus ADflagUL79 (derived from pADflagUL79) or ADwt (derived from pADwt) at an MOI 
of 3.  Infected culture supernatants were collected at indicated days post infection and virus 
titers were determined by TCID50 assay.  The mean virus titers were derived from two 
independent experiments and two technical replicates.  Standard deviations were presented.  
The detection limit is indicated by the dashed line.  (C) Viral protein expression profile.  
HFFs were infected as described in (B), and harvested at indicates times post infection.  
Accumulations of host and viral proteins were determined by immunoblot analysis.  FLAG-
tagged pUL79 was detected by anti-FLAG antibody.  Actin was used as a loading control.  
Representative results from three independent experiments are shown.  (D) Polyacrylamide 
gel electrophoresis to resolve pUL79 protein complexes.  HFFs were infected as described in 
(B), and at 72 hpi, cell lysates were prepared for immunoprecipitation using an anti-FLAG 
antibody.  Immunoprecipitated proteins were resolved on a gradient polyacrylamide gel and 
silver stained.  Protein bands containing RNAP II subunits identified by mass spectrometry 
are indicated.  Molecular size markers (in kilodaltons) are shown. 
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Figure 3.2.  pUL79 interacts with the RNAP II protein complex.  In (A-B), HFFs were 
infected as described in Figure 3.1, and at 72 hpi cell lysates were immunoprecipitated using 
either an anti-FLAG antibody (A) or anti-Rpb1 antibody N-20 (B).  Immunoprecipitated 
proteins and lysate inputs were analyzed by immunoblotting.  To examine the efficiency of 
nuclease digestion, the immunoprecipitated samples were also analyzed on an ethidium 
bromide (EtBr)-stained agarose gel.  In (C-D), nuclear lysates from HEK-293T cells 
transiently expressing HA-tagged pUL79 or empty vector control were prepared at 72 hours 
post transfection.  Lysates were immunoprecipitated using either anti-HA antibody (C) or 
anti-Rpb1 antibody 8WG16 (D).  Immunoprecipitated proteins and lysate inputs were 
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analyzed by immunoblotting.  The clone names of antibodies used in immunoblot analysis 
are shown.  Representative results from three independent experiments are presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!! 95!
 
Figure 3.3.  pUL79 does not alter protein accumulations of RNAP II.  HFFs were 
infected with ADddUL79 at an MOI of 3 in the presence or absence of 1 µM Shield-1 
(Shld1).  Cells were harvested at different times post infection and protein accumulation was 
analyzed by immunoblot analysis with antibodies recognizing various subunits and isoforms 
of RNAP II, cellular CTD kinases (cyclin T1, CDK9), or viral proteins (immediate-early 
protein IE1, early-late protein pUL44, late protein pp71).  The protein accumulation of the 
ddFKBP tagged pUL79 were monitored by an antibody recognizing the FKBP-epitope.  
Representative results from three independent experiments are shown. 
 
 
Figure 3  
IE1 
Actin 
Rpb1 (N-20) 
pSer5/pSer2-CTD (H-14) 
Shld1 
pSer2-CTD (ab5095) 
pUL44 
pp71 
ddFKBP-pUL79 
Rpb2 (S-20) 
pSer5-CTD (3E8) 
Unphos. CTD (8WG16) 
cyclin T1 
CDK9 
M
oc
k ADddUL79 
1h 24h 48h 72h 
+ + + + - - - - 
!! 96!
 
Figure 3.4.  pUL79 alters RNAP II occupancy at viral loci.  HFFs cells were infected with 
ADddUL79 at an MOI of 3 in the presence or absence of 1 µM Shld1.  Cell extracts were 
prepared at 72 hpi and analyzed by ChIP assay using rabbit anti-RNAP II antibody N-20.  
Normal rabbit IgG was included as a control for non-specific immunoprecipitation.  Amounts 
of input and precipitated (output) DNAs were quantified by qPCR with primers specific for 
indicated viral loci or human GAPDH.  The output-to-input DNA ratios were determined 
from four independent ChIP experiments with standard deviations calculated by Prism 6 
software.  Statistical analysis was performed using Student’s t test (**, P < 0.01; ***, P < 
0.005; ****, P < 0.0001; NS, not significant). 
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Figure 3.5.  pUL79 does not alter a particular phosphorylated form of the RNAP II 
CTD domain.  HFFs cells were infected with ADddUL79 at an MOI of 3 in the presence or 
absence of 1 µM Shld1.  Cell extracts were harvested at 72 hpi and analyzed by ChIP assays.  
Rabbit antibody to pSer2 CTD, rat antibody to pSer5-CTD, and mouse antibody to non-
phosphorylated CTD (8WG16) were used in ChIP assays.  Normal rabbit, rat, and mouse 
IgGs were included as controls for non-specific precipitation, respectively.  
Immunoprecipitated DNAs were analyzed as described in Figure 3.4 and the output-to-input 
DNA ratios were presented in (A).  In addition, the immunoprecipitated amount of each 
phosphor-isoform of RNAP II CTD relative to that of total RNAP II (immunoprecipitated 
with antibody N-20) was also calculated and presented in (B).  Data from four independent 
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experiments were collected with standard deviations calculated by Prism 6 software.  
Statistical analysis was performed using Student’s t test (*, P < 0.05; **, P < 0.01; ***, P < 
0.005). 
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Figure 3.6.  pUL79 alters the rate of transcriptional elongation at viral loci.  HFFs were 
infected with ADddUL79 at an MOI of 3 in the presence or absence of 1 µM Shld1 (indicated 
by "+" or "-" sign, respectively).  Nuclear extracts were prepared at 72 hpi and analyzed by 
nuclear run-on (NRO) assays.  Transcription elongation was allowed to resume for 30 
minutes in the presence of biotin-labeled UTP, labeled RNA was isolated, and their amounts 
were determined by RT-qPCR.  In addition, accumulations of total RNAs were also 
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determined by RT-qPCR.  The normalized amounts of viral run-on transcripts or total 
transcripts in the presence of Shld1 were set at 1 for run-on assay or total transcript 
accumulation analysis, respectively.  Relative amounts of total and run-on transcripts for viral 
genes MIE (A), UL44 (B), UL54 (C), UL99 (D), UL32 (E), cellular genes GAPDH (F), and 
RPL30 (G) were presented.  Data from three independent experiments were collected and 
standard deviations were calculated by Prism 6 software.  Statistical analysis was performed 
using Student’s t test (**, P < 0.01; ***, P < 0.005; NS, not significant). 
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Figure 3.7.  Potential role of pUL79 in RNAP II-mediated viral transcription.  During 
late times of viral infection where pUL79 is expressed, we propose two models where pUL79 
may act as an elongation factor to facilitate viral transcription.  (A) In the “promoter 
clearance” model, pUL87, pUL92, pUL95, and potentially other viral factors (shown as red 
dashed circles) form viral protein pre-initiation complexes (vPIC) to recruit RNAP II to viral 
promoters.  Once transcription initiates, pUL79 interacts with the vPIC to release RNAP II 
from the vPIC for efficient elongation.  In the absence of pUL79, RNAP II is unable to 
dissociate from vPIC and fails to recruit elongation factors for continued transcription.  (B) In 
the "epigentic reading" model, pUL79 acts as an epigenetic reader to recognize chromatin 
modification(s) to facilitate RNAP II elongation.  During late times of infection, newly 
synthesized viral DNA is wrapped with specific histone modifications (shown as purple 
dashed ovals).  pUL79 recognizes these modifications, and then dissociates viral DNA from 
chromatin binding, with or without other cellular/viral factors, to facilitate RNAP II 
Figure 7 
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elongation.  In the absence of pUL79, RNAP II is unable to pass through the unopened 
chromatin, resulting in transcriptional stalling on viral loci. 
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TABLES 
 
Protein ID Description Size (kDa) Expectationa Peptide count 
HCMV transactivators    
B8YEB2  pUL87 104.7 0 44 
B8YEB9  pUL95 57.2 9.4×10E-37 26 
D2K4K7 pUL92 22.5 6.60×10E-24 6 
A8T7F6  pUL79 33.8 1.5×10E-40 12 
HCMV DNA synthesis    
Q69214  UL112/113 (pp34) 28.3 2.7×10E-14 7 
D2K4M1  UL112 (pp84) 70.2 3.2×10E-15 6 
D2K5E9  pUL44 (DNA pol. processivity factor) 46.2 8.0×10E-6 2 
C8CFZ3  IRS1 (tegument protein) 91.7 9.6×10E-3 1 
Other HCMV proteins    
D2K3R0  pUL104 (capsid portal protein) 78.4 2.5×10E-35 10 
D2K4X8  pUL85 (capsid triplex subunit) 34.5 2.8×10E-16 7 
D2K4H6  pUL150 (nuclear egress protein) 43.1 1.1×10E-05 2 
Q1KQ04  pUL49 63.8 0.01 1 
Cellular RNA polymerase II    
RPB2_Human Subunit Rpb2 133.8 8.8×10E-101 29 
RPB1_Human Subunit Rpb1 217 2.6×10E-81 27 
RPB3_Human Subunit Rpb3 31.4 1.1×10E-20 6 
RPB5_Human Subunit Rpb5 24.5 6.8×10E-07 2 
Ribosome biogenesis    
RL7A_Human 60S ribosomal protein L7a 29.9 4.6×10E-07 3 
RL21_Human 60S ribosomal protein L21a 18.5 2.1×10E-11 3 
RS2_Human 40S ribosomal protein RPS2 31.3 6.7×10E-05 3 
RS3A_Human 40S ribosomal protein RPS3a 29.9 4.4×10E-04 3 
RL23_Human 60S ribosomal protein RPL23 14.8 3.9×10E-04 2 
RL23A_Human 60S ribosomal protein RPL23a 17.6 3.6×10E-04 1 
RL24_Human 60S ribosomal protein L24 17.7 8.8×10E-01 1 
RS26L_Human 40S ribosomal protein S26-like 1 12.9 9.8×10E-03 1 
RS27A_Human Ubiquitin-40S ribosomal protein S27a 17.9 0.23 1 
Other cellular proteins    
ACTB_Human  Actin, cytoplasmic 1 41.9 4.6×10E-51 15 
ACTN1_Human Alpha-actinin-1 102.9 8.4×10E-10 3 
EF1A1_Human Elongation factor 1-alpha 1 50.1 4.8×10E-3 3 
ANXA5_Human Annexin A5 35.9 9.7×10E-3 3 
H2A1B_Human Histone H2A type 1-B/E 14.12 0.15 3 
RECQ4_Human ATP-dependent DNA helicase Q4 132.9 0.25 1 
a Expectation value for peptide match (i.e. the number of times expected to obtain an equal or higher score, purely by chance).  
A lower value indicates a higher likelihood of the interaction. 
 
Table 3.1.  pUL79 protein partners identified by mass spectrometry 
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Antigen Clone No Source Type Amounta Dynabeadb 
Normal mouse IgG (negative 
control)  
100005292 Invitrogen Mouse 
polyclonal 
2.5 µg Protein A/G 
Normal rabbit IgG (negative 
control)  
100005291 Invitrogen Rabbit 
polyclonal 
1 µg Protein A/G 
Normal rat IgG (negative 
control)  
NI04 Millipore  Rat 
polyclonal 
5 µg Protein G 
RNAP II, CTD phosphorylated 
Ser2 (pSer2)  
ab5095 Abcam  Rabbit 
polyclonal 
1 µg Protein A/G 
RNAP II, CTD phosphorylated 
Ser5 (pSer5)  
3E8 Millipore  Rat 
monoclonal 
5 µg Protein G 
RNAP II, unphosphorylated 
CTD 
8WG16 Abcam Mouse 
monoclonal 
2.5 µg Protein A/G 
RNAP II, total N-20 Santa Cruz Rabbit 
polyclonal 
1 µg Protein A/G 
a Amount of antibody used in a 2.5×105-cell sample. 
b Type of Fc-binding proteins conjugated to Dynabeads. 
 
Table 3.2.  Antibodies used in chromatin immunoprecipitation assays 
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Primer ID Sequence (5' - 3') Target Reference 
YD-Pri692 TTTTCTCACCGAGGAACCTTTC UL44, forward (27) 
YD-Pri693 CCGCTGTTCCCGACGTAAT UL44, reverse (27) 
YD-Pri744 CTGTTGCTGTAGCCAAATTCGT GAPDH, forward (52) 
YD-Pri745 ACCCACTCCTCCACCTTTGAC GAPDH, reverse (52) 
YD-Pri2074 GGTTTCTGGCTCGTGGATGTCG UL32, forward (52) 
YD-Pri2075 CACACAACACCGTCGTCCGATTAC UL32, reverse (52) 
YD-Pri2076 GTGTCCCATTCCCGACTCG UL99, forward (52) 
YD-Pri2077 TTCACAACGTCCACCCACC UL99, reverse (52) 
YD-Pri2489 CTTACGGGACTTTCCTACTTG MIE, forward a (46) 
YD-Pri2490 CGATCTGACGGTTCACTAA MIE, reverse a (46) 
YD-Pri2491 CCTAGTGTGGATGACCTA MIE, forward (46) 
YD-Pri2492 GTGACACCAGAGAATCAG MIE, reverse (46) 
YD-Pri2493 CACCAAAGACACGTCGTT UL54, forward a (46) 
YD-Pri2494 GTCCTTTGCGACCAGAAT UL54, reverse a (46) 
YD-Pri2495 GTGTGCAACTACGAGGTA UL54, forward (46) 
YD-Pri2496 GACAGCACGTTGGTTACA UL54, reverse (46) 
YD-Pri2511 GGGTGTGGCGCTACGGGTTACAAA UL75, forward a  
YD-Pri2512 ATGGCTTACCCGCGTGTCCC UL75, reverse a  
YD-Pri2521 GTGTCCATCAAAGAGGATACAG UL75, forward  
YD-Pri2522 AAACCACTCCACACGACTGG UL75, reverse  
YD-Pri2527 CCACGATGGACACCATCATC UL32, forward a  
YD-Pri2528 AGAAAACCGCGTATCCGCCT UL32, reverse a  
YD-Pri3021 GTAACCCGTTGAACCCCATT 18s rRNA, forward  
YD-Pri3022 CCATCCAATCGGTAGTAGCG 18s rRNA, reverse  
YD-Pri3023 CAAGGCAAAGCGAAATTGGT RPL30, forward b (34) 
YD-Pri3024 GCCCGTTCAGTCTCTTCGATT RPL30, reverse b (34) 
YD-Pri3027 CTGGGCAGTTGTTAGCGAGA RPL30, forward c (34) 
YD-Pri3028 GTCGCTGGAGTCGATCAACT RPL30, reverse c (34) 
Hs03929097_g1 Taqman probe for ChIP (Invitrogen) GAPDH  a Promoter regions 
b Used in RT-qPCR for nuclear run-on assay only 
c Used in RT-qPCR for total transcript quantification 
 
Table 3.3.  Primers and probes used in ChIP and RT-qPCR analysis 
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Summary 
     As an important human pathogen, HCMV possesses many essential genes whose 
functions remain unknown.  In this dissertation, I characterize the function and potential 
mechanism of a novel essential protein pUL79 during viral infection.  
     To characterize the function of pUL79 during viral infection, we applied the ddFKBP-
mediated, Shield-1-regulated protein genetic approach(3) to investigate its role during 
HCMV replication(20).  Without pUL79, HCMV failed to replicate.  Systemic analysis of 
ADddUL79 infection in the absence of Shield-1 showed that UL79 was required at late 
stages of HCMV infection.  Acting as a viral early-late protein, pUL79 localized into viral 
replication compartments where viral replication and late gene transcription took place.  In 
the absence of pUL79, the immediate-early and early viral proteins as well as viral DNA 
accumulated normally.  However, accumulations of viral late transcripts and proteins were 
dramatically reduced.  We conclude that UL79 acts as a viral transactivator after DNA 
replication to promote the accumulation of late viral transcripts. 
     To further dissect the potential mechanisms of pUL79 to regulate viral late gene 
expression, we applied an unbiased proteomic analysis to identify its protein partners.  In 
chapter 3, we showed that HCMV pUL79 interacts with human RNAP II as well as other 
viral factors involved in late gene expression during viral infection.  Since HCMV genes are 
transcribed by RNAP II during viral infection, we focused on the nature of the pUL79-RNAP 
II interactions, finding that pUL79 does not alter the protein levels of RNAP II or its 
recruitment to viral promoters.  However, during late times of infection, pUL79 helps RNAP 
II to efficiently elongate along the viral DNA template to transcribe HCMV genes.  While 
viral genes were regulated in this manner, we found that host genes are not regulated by this 
pUL79-mediated mechanism.  Therefore, our study identifier a previously uncharacterized 
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mechanism in which RNAP II activity is modulated by the viral factor pUL79, and 
potentially other viral factors as well, for coordinated viral transcription.   
     Altogether, our significant finding is that pUL79 plays a critical role to drive viral late 
transcription after viral DNA replication.  Since pUL79 is functionally conserved among 
beta- and gamma- herpesviruses, this provides an opportunity to understand the previously 
uncharacterized regulation of viral late transcription of these two viral sub-families.  
Inhibition of pUL79 and homologs represents a novel anti-viral therapeutic target against 
both beta- and gamma- herpesviruses.  Moreover, since the function of pUL79 is mediated by 
its interaction with RNAP II, our study also serves as a novel probe to elucidate the 
mechanistic actions of the RNAP II complex during transcription initiation, elongation, or 
potentially termination. 
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Future Directions 
Although we have taken important steps to characterize the function of pUL79, the precise 
mechanism by which pUL79 regulates HCMV late gene transcription awaits further 
investigation.  Below we discuss future experiments that may aid in this discovery. 
 
How does pUL79 specifically regulates transcription of viral loci during late times of 
infection?  In chapter 3, we show that pUL79-mediated transcriptional regulation is limited 
to viral but not host genes.  The transcription rates of the host genes investigated, including 
GAPDH and RPL30, were not regulated by pUL79 (Figures 3.6F and 3.6G).  Consistent with 
these results, RNAP II did not stall on the GAPDH locus in the absence of pUL79 (Figure 
3.4).  We suspect that the specific regulation of viral genes by pUL79 may be partially due to 
its localization.  pUL79 is enriched in the replication compartments where late viral 
transcription occurs, which suggests that pUL79 primarily associates with RNAP II 
transcribing viral genes(20).  A recent study showed that the viral late promoters encode a 
non-canonical TATA box sequence that is well-conserved among late promoters of beta- and 
gamma-herpesviruses(9).  EBV BcRF1, homolog of HCMV pUL87, is a viral TATA-box 
binding protein which preferentially bound to this non-canonical TATA box over the 
canonical sequence, suggesting that the viral transcription machinery directs RNAP II to viral 
late promoters during late stages of viral infection(9).  In HCMV, multiple characterized viral 
late promoters also encode the same non-canonical TATA sequences which may allow for 
the targeting of RNAP II to their loci(8, 11-14, 16, 23).  However, in the absence of pUL79, 
we also observed an overall drop in transcription rates among all different kinetic classes of 
viral genes during late times of infection (Figure 3.6).  For example, UL54 is an early-late 
gene with a classical TATA sequence(12, 13).  However, the transcription rate of UL54 still 
decreased in the absence of pUL79 (Figure 3.6C).  We hypothesize that, during late stage of 
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viral infection, BcRF1 and its homologs (ex. pUL87 in HCMV) are expressed and form 
complex with pUL79 homologs.  This viral protein complex, located in the viral replication 
compartment, replaces host TBP and other RNAP II associated factors to direct RNAP II 
transcribing viral genes belong to different kinetics.  However, the binding preference of 
BcRF1 promotes RNAP II to transcribe more viral early-late and late genes during late times 
of viral infection.  Further characterization is needed to dissect how pUL79 associates with 
these viral factors to regulate the rate of viral transcription. 
 
How does pUL79 modulate RNAP II elongation?  We considered two potential roles that 
pUL79 might play.  First, pUL79 might act as a modulator to increase promoter clearance, a 
step in which RNAP II transfers from the initiation state to the elongation state.  During the 
transcription cycle, RNAP II is recruited to promoters by host TATA-box binding protein 
(TBP) and other general transcription factors (GTFs) to form the pre-initiation complex 
(PIC).  The PIC helps position RNAP II over transcription start sites, denatures DNA, and 
positions DNA into the RNAP II active site for transcription(5).  After transcription initiates, 
the RNAP II dissociates from PIC and recruits elongation factors for efficient transcription.  
The dissociation of RNAP II from PIC is mediated by TFIIH and other cellular kinases to 
facilitate exchange between initiation factors and elongation factors(1, 25).  Inefficient 
dissociation reduces the rate of RNAP II elongation with subsequent failure to transcribe 
genes(1).  Several viral proteins have been shown to be viral transcription initiation factors 
and to potentially form a unique viral PIC.  For example, UL87 and its homologs in beta- and 
gamma- herpesviruses were found to be viral TBPs and regulate late transcript 
accumulation(2, 9).  MHV68 ORF30 and ORF34, homologs of HCMV UL91 and UL95, 
were also shown to be required for RNAP II recruitment to viral late promoters(24).  EBV 
Rta, a homolog of CMV UL112/113, was found to associate with viral late promoters during 
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late times of viral infection (10).  All of these viral factors might participate in viral PIC 
assembly by mediating RNAP II promoter positioning (Figure 3.7A).  Strikingly, pUL79 co-
purified with the factors mentioned above (Table 3.1).  In the absence pUL79, the recruitment 
of RNAP II to viral promoters was not influenced, indicating that pUL79 is not required for 
RNAP II initiation (Figure 3.4).  However, the elongation rates of RNAP II at viral loci 
dropped, suggesting that pUL79 is essential for certain transcription steps downstream of 
initiation.  Since the viral PIC complex might not be recognized by host dissociation factors, 
we hypothesize that pUL79 plays a role in the release of RNAP II from viral PIC prior to 
elongation.  The simplified model is shown in Figure 3.7A.  To test this hypothesis, further 
analysis is required to determine the composition of RNAP II/viral PIC as well as their 
distribution on the viral DNA.  
     Second, pUL79 could play a role in the epigenetic regulation to modulate viral 
transcription.  Previous studies showed that HCMV undergoes dedicated histone modification 
during infection, including increases in histone 3 acetylation (H3Ac) and histone 3 lysine 9 
(H3K9) methylation, that activate gene expression(17).  After the onset of viral DNA 
replication, newly synthesized viral DNA is wrapped with histone 3 lysine 4 methylation 
(H3K4me2), a modification that favors active transcription, suggesting that epigenetic 
regulation is involved in viral late transcription(18).  However, pUL79 was not required for 
methylating H3K4(18).  Notably, we showed that the rate of RPL30 transcription is not 
regulated by pUL79 (Figure 3.6G).  RPL30 is a host ribosomal protein whose epigenetic 
modification was similar to viral DNA during late times of viral infection(18).  Therefore, if 
pUL79 is an epigenetic reader for late viral transcription, it might recognize an as of yet 
uncharacterized histone modifications unique to viral DNA.  We hypothesize that pUL79 act 
as an epigenetic reader to recognize these unique modified histones and unwrap viral DNA 
packaged by histones to facilitate RNAP II elongation (Figure 3.7B). 
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How does pUL79 interacts with RNA polymerase II (RNAP II) complex?  To determine 
how pUL79 interacts with RNA polymerase II, we created truncation mutants targeting N-
terminus and C-terminus of pUL79 (Figure 4.1A), and tested the ability of mutant pUL79 
proteins to interact with RNAP II in 293T cells (Figure 4.1B).  Both mutants were expressed 
at 293T cells.  However, N-terminal truncation mutant had lower expression level, suggesting 
that the N-terminus of pUL79 might be required for proper protein folding and stability.  As 
expected, full-length pUL79 co-immunoprecipitated with RNAP II.  In contrast, both N- and 
C- terminuses mutants were unable to do so.  We concluded that both N- and C- terminuses 
of pUL79 are required for pUL79-RPB1 interaction.  To further explore how pUL79 interacts 
with RNAP II complex, we decided to focus on RPB1, the largest subunit of RNA 
polymerase II complex, with the help of bioinformatics tools. 
        In chapter 3, we identified RPB1 as one of pUL79 interacting partners.  RPB1 plays a 
major role in the RNA polymerase II transcription cycle.  The C-terminal domain (CTD) of 
Rpb1 functions as a binding platform for the recruitment of transcription-associated factors.  
During the transcription cycle, the Rpb1 CTD undergoes dynamic phosphorylation that 
defines the ability of the RNA pol II transcriptional complex to recruit the appropriate set of 
mRNA-processing and histone-modifying factors(4, 6).  The pUL79-RPB1 interaction 
suggests that pUL79-regulated RNAP II transcription elongation might be mediated by this 
interaction.  To test this hypothesis, we performed bioinformatics analysis (MAFFT program) 
to identify the potential domain of pUL79 required for binding to Rpb1.  We found that 
pUL79 potentially has conserved domains similar to a CTD-interacting domain (CID) present 
in proteins such as Pcf11 and SCAF4/8, which are essential and evolutionarily conserved 
factors for polyadenylation-dependent and -independent 3’-RNA processing, respectively(7, 
15) (Figure 4.2A).   
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     To confirm this finding, we first created pUL79 mutants that contained an internal 
deletion covering the CID-like domains (pUL79 del aa. 40-46, del. aa. 96-103, del. aa. 192-
200, see Figure 4.1).  We examined their ability to complement pUL79 null virus and interact 
with Rpb1.  All three mutants failed to complement the growth of pUL79 null virus or rescue 
the defect in late protein accumulation (Figure 4.3).  We also performed co-
immunoprecipitation experiments to test the interaction between Rbp1 and these pUL79 
mutants.  The preliminary study also suggests that all three mutants fail to interact with Rpb1 
during virus infection (Figure 4.2).  However, we noticed that these pUL79 mutant proteins 
were expressed at low levels, suggesting that the internal-deletion mutants might be unstable 
and degraded.  To overcome this, we created two different pUL79 mutant libraries.  First, we 
created additional internal-deletion mutants before and after the CID-like domains.  We 
expected that these mutants would serve as controls and help us understand whether the CID-
like domains are critical for protein folding and stability.  Second, we created site-directed 
mutagenesis mutants covering most of the three CID-like domains that might avoid protein 
stability issues and allows us pinpoint the critical residues of protein interaction.  The 
preliminary results of complementation tests show several loci within or outside CID-like 
domains are important for viral growth (Figure 4.4B and 4.4C).  However, we noticed that 
several pUL79 mutant proteins, even when expressed at similar levels compared to the wild-
type pUL79, failed to translocate into nucleus (Figure 4.4D).  Further analyses are required to 
define whether these regions are critical for proper protein folding to pass through nuclear 
pore.  Meanwhile, further analyses, including co-immunoprecipitation and in vitro binding 
assays, will help to confirm whether and how pUL79 interacts with RNAP II complex 
through RPB1 CTD domain. 
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Interactions between pUL79 and viral DNA replication factors.  During lytic infection, 
HCMV genes are expressed in a highly ordered temporal cascade.  The transcript 
accumulation of early genes is independent of viral DNA synthesis; however, the continued 
accumulation of a subset of these genes (i.e, early-late) at late times is enhanced by the onset 
of viral DNA synthesis(22).  Following viral DNA synthesis, late viral genes start to 
transcribe.  In chapter 2, we showed that the pUL79-mediated viral transcription requires 
DNA replication(20).  Over-expression of neither pUL79 alone nor the combination of all 
late gene regulators currently identified in cells altered the expression kinetics of viral genes, 
especially viral late genes(19, 20).   In chapter 3, we found that pUL79 co-purified with viral 
DNA replication factors.  It is possible that viral DNA replication directs viral late 
transcription through the direct interactions between replication factors and pUL79.  
Interestingly, a recent study of the HCMV latent transcriptome in CD14+ and CD34+ cells 
showed that pUL79, pUL87, pUL95 were consistently expressed in latently-infected 
cells(21).  Further analysis will help to determine whether and how these beta-gamma genes 
(pUL79, pUL87, pUL92, or pUL95) act as sensors of viral DNA replication to direct late 
transcription during acute infection and viral reactivation during viral latency.  
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Figure 4.1. Both N- and C- terminuses of pUL79 are required for pUL79-RNAP II 
interaction.  (A) Diagram of pUL79 truncation and interal-deletion mutants analyzed in this 
study.  (B) HA-tagged UL79 wild-type and truncation mutant proteins were expressed in 
293T cells by transfection.  Cells were collected at 72 hours and lysates were 
immunoprecipiated with RNAP II antibody (RPB1).  Cell lysates (Input) and eluted proteins 
(IP:RPB1) were analyzed by immunoblotting. 
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Figure 4.2. pUL79 potentially contains RPB1 CTD-binding domains (A) Amino acid 
alignment of UL79 protein and the CTD-binding domains (CID) of two human transcription 
termination factors, SCAF4 and SCAF8, using the MAFFT program.  Amino acid residues 
conserved in all three proteins are indicated in black, and residues conserved in any two 
proteins were indicated in gray.  The conserved residues required for CTD-CID interaction 
are boxed in red.  (B) MRC5 cells over-expressing pUL79 wild-type and internal deletion 
mutants were infected with ADddUL79 at a MOI of 3 in the absence of Shield-1.  Cell 
lysates were collected at 72 hpi, immunoprecipitated with anti-HA antibody, and analyzed by 
immunoblotting. 
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Figure 4.3. Deletion of pUL79’s CID-like domains reduces viral late protein 
accumulation and viral progeny production. (A) MRC5 cells over-expressing HA-tagged 
pUL79 wild-type or internal deletion mutants were infected with ADddUL79 at a MOI of 3 
in the absence of Shield-1.  Cell lysates were harvested at 72 hpi and the expression profile of 
viral proteins was analyzed by immunoblotting.  (B) The supernatant was also harvested 7 
days post infection and the presence of viral progeny was analyzed by TCID50 assay. The 
detection limits of TCID50 assay are indicated by dashed lines in the graphs. 
 
#
#
#
#
C.  
ADddUL79 
+
+
+
+
+
α-IE1 (72hpi) 
α-pp71 (72hpi) 
α-pp28 (72hpi) 
α-HA (0 hpi) 
α-actin (0 hpi) 
α-UL44 (72hpi) 
vector 
HA-pUL79  
Figure 3.  
HA-pUL79 del. aa. 40-46 
HA-pUL79 del. aa. 96-103 
HA-pUL79 del. aa. 192-200 
ve
cto
r a
lon
e
wi
ld-
typ
e (
p3
0)
de
l. a
a. 
40
-46
 (1
D)
de
l. a
a. 
96
-10
3 (
2D
)
de
l. a
a. 
19
2-2
00
 (3
D)
aa
. 1
01
-10
2 R
Q-
AA
 (2
M)
aa
. 1
81
-18
2 R
H-
EE
 (S
1)
aa
. 1
93
-19
4 W
G-
SS
 (S
2)
aa
. 1
85
-18
6 A
E-
SS
 (S
3)
aa
. 1
89
-19
0 E
P-
RR
 (S
4)
aa
. 1
93
-19
4 R
I-E
E (
S6
)
aa
. 1
95
-19
6 I
C-
EE
 (S
7)
aa
. 1
97
-19
8 Q
K-
II (
S8
)
aa
. 1
99
-20
0 M
W-
EE
 (S
9)
aa
. 2
03
-20
5 Y
LI-
RR
R 
(S
10
)
102
103
104
105
106
107
TC
ID
50
 p
er
 m
l (
lo
g 1
0)
ve
cto
r a
lon
e
wi
ld-
typ
e
de
l. a
a. 
40
-46
de
l. a
a. 
96
-10
3
de
l. a
a. 
19
2-2
00
102
103
104
105
106
107
TC
ID
50
 p
er
 m
l (
lo
g 1
0)
MOI 1.0, 7 dpi
! 124!
A.#
#
B.#
#
#
#
wi
ld-
typ
e
ve
cto
r a
lon
e
de
l. a
a. 
40
-46
de
l. a
a. 
96
-10
3
de
l. a
a. 
17
4-1
82
de
l. a
a. 
19
2-2
00
de
l. a
a. 
20
1-2
10
de
l. a
a. 
23
1-2
39
de
l. a
a. 
24
0-2
45
de
l. a
a. 
24
6-2
50
de
l. a
a. 
25
1-2
55
de
l. a
a. 
25
6-2
63
de
l. a
a. 
26
3-2
71
de
l. a
a. 
28
9-2
95
102
103
104
105
106
107
108
TC
ID
50
 p
er
 m
l (
lo
g 1
0)
! 125!
C.#
#
D.#
#
Figure 4.4. Identification of residues critical to pUL79-RPB1 mediated viral replication. 
(A) Diagram of pUL79 interal-deletion and side-directed mutagenesis mutants analyzed in 
this study.  (B&C) MRC5 cells over-expressing HA-tagged pUL79 internal deletion (B) or 
site-directed mutagenesis (C) mutants were infected with ADddUL79 at a MOI of 1 in the 
absence of Shield-1.  The supernatant was also harvested 7 days post infection and the 
presence of viral progeny was analyzed by TCID50 assay. The detection limits of TCID50 
assay are indicated by dashed lines in the graphs. (D) HA-tagged UL79 wild-type or 
truncation mutant proteins were expressed in 293T cells by transfection.  Cell lysates were 
collected at 72 hours and cellular nuclear extracts were extracted for immunoblotting 
analysis. 
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